=> d stat que l3; d his full
L1 STR



VAR G1=15/21/22
VAR G2=O/S/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 14
GGCAT IS MCY UNS AT 21
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1-X2 N AT 14
ECOUNT IS X2 N AT 21

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L3 45 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 124127 ITERATIONS 45 ANSWERS
SEARCH TIME: 00.00.02

(FILE 'HOME' ENTERED AT 15:44:30 ON 18 AUG 2005)

FILE 'REGISTRY' ENTERED AT 15:44:43 ON 18 AUG 2005
L1 STR
L2 1 SEA SSS SAM L1
D SCAN
L3 45 SEA SSS FUL L1
SAVE TEMP L3 WAR810FULL/A
E C19H16N4O3/MF
E C19H16N4O3?/MF
L4 1222 SEA ABB=ON C19H16N4O3?/MF
L5 0 SEA ABB=ON L3 AND L4

FILE 'CAPLUS' ENTERED AT 15:49:39 ON 18 AUG 2005
L6 4 SEA ABB=ON L3

FILE 'REGISTRY' ENTERED AT 15:49:44 ON 18 AUG 2005
L7 ANALYZE L3 1- LC : 6 TERMS
D

FILE 'REGISTRY' ENTERED AT 15:51:11 ON 18 AUG 2005
D STAT QUE L3
D QUE NOS L5

```
     FILE 'CAPLUS, CASREACT, USPATFULL, USPAT2, TOXCENTER' ENTERED AT 15:51:11
     ON 18 AUG 2005
L8            14 SEA ABB=ON  L3
L9             8 DUP REM L8 (6 DUPLICATES REMOVED)
                     ANSWERS '1-4' FROM FILE CAPLUS
                     ANSWERS '5-8' FROM FILE USPATFULL
               D IBIB ED ABS HITSTR 1-8

     FILE 'HOME' ENTERED AT 15:51:40 ON 18 AUG 2005
               D SAVED
               D STAT QUE L3


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   17 AUG 2005  HIGHEST RN 860672-09-9
     DICTIONARY FILE UPDATES:  17 AUG 2005  HIGHEST RN 860672-09-9

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     Experimental and calculated property data are now available. For more
     information enter HELP PROP at an arrow prompt in the file or refer
     to the file summary sheet on the web at:
     http://www.cas.org/ONLINE/DBSS/registryss.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 18 Aug 2005  VOL 143 ISS 8
```

FILE LAST UPDATED: 17 Aug 2005 (20050817/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CASREACT

FILE CONTENT:1840 - 14 Aug 2005 VOL 143 ISS 7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

****
* *
* CASREACT now has more than 9.2 million reactions *
* *
****

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 16 Aug 2005 (20050816/PD)
FILE LAST UPDATED: 17 Aug 2005 (20050817/ED)
HIGHEST GRANTED PATENT NUMBER: US6931661
HIGHEST APPLICATION PUBLICATION NUMBER: US2005177917
CA INDEXING IS CURRENT THROUGH 17 Aug 2005 (20050817/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 16 Aug 2005 (20050816/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 16 Aug 2005 (20050816/PD)
FILE LAST UPDATED: 17 Aug 2005 (20050817/ED)
HIGHEST GRANTED PATENT NUMBER: US2005113906
HIGHEST APPLICATION PUBLICATION NUMBER: US2005177917
CA INDEXING IS CURRENT THROUGH 17 Aug 2005 (20050817/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 16 Aug 2005 (20050816/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

USPAT2 is a companion file to USPATFULL. USPAT2 contains full text of the latest US publications, starting in 2001, for the inventions covered in USPATFULL. USPATFULL contains full text of the original published US patents from 1971 to date and the original applications from 2001. In addition, a USPATFULL record for an invention contains a complete list of publications that may be searched in standard search fields, e.g., /PN, /PK, etc.

USPATFULL and USPAT2 can be accessed and searched together through the new cluster USPATALL. Type FILE USPATALL to enter this cluster.

Use USPATALL when searching terms such as patent assignees, classifications, or claims, that may potentially change from the earliest to the latest publication.

FILE TOXCENTER

FILE COVERS 1907 TO 16 Aug 2005 (20050816/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields. See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary. See http://www.nlm.nih.gov/mesh/ and http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html for a description of changes.

=>

```
=> fil reg; d stat que l3; d que nos l5; fil capl casre uspatf uspat2 toxcenter; s
l3
FILE 'REGISTRY' ENTERED AT 15:51:11 ON 18 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   17 AUG 2005  HIGHEST RN 860672-09-9
DICTIONARY FILE UPDATES:  17 AUG 2005  HIGHEST RN 860672-09-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html
```

L1 STR







Hy = heterocycle

```
VAR G1=15/21/22
VAR G2=O/S/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT  14
GGCAT   IS MCY  UNS  AT  21
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M1-X2 N  AT  14
ECOUNT  IS X2 N  AT  21
```

Heterocycle at node 14 is monocyclic, unsaturated & has 1-2 nitrogens

Heterocycle at node 21 is monocyclic, unsaturated & has a maximum of 2 nitrogens

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE
L3            45 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED  124127 ITERATIONS                          45 ANSWERS
SEARCH TIME: 00.00.02



L1               STR
L3            45 SEA FILE=REGISTRY SSS FUL L1
L4          1222 SEA FILE=REGISTRY ABB=ON  C19H16N4O3?/MF
L5             0 SEA FILE=REGISTRY ABB=ON  L3 AND L4



FILE 'CAPLUS' ENTERED AT 15:51:11 ON 18 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 15:51:11 ON 18 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:51:11 ON 18 AUG 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:51:11 ON 18 AUG 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 15:51:11 ON 18 AUG 2005
COPYRIGHT (C) 2005 ACS


L8           14 L3

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9             8 DUP REM L8 (6 DUPLICATES REMOVED)
                 ANSWERS '1-4' FROM FILE CAPLUS
                 ANSWERS '5-8' FROM FILE USPATFULL

=> d ibib ed abs hitstr 1-8; fil hom

L9   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2005 ACS on STN  DUPLICATE 1
ACCESSION NUMBER:         2003:301079  CAPLUS
DOCUMENT NUMBER:          138:304310
TITLE:                    Preparation of 3-[4-(heterocyclyl)-pyrrol-2-
                          ylmethylidene]-2-indolinone derivatives as kinase
                          inhibitors
INVENTOR(S):              Mattson, Matthew; Vojkovsky, Tomas; Liang, Congxin;
                          Tang, Peng Cho; Guan, Huiping
PATENT ASSIGNEE(S):       Sugen, Inc., USA
SOURCE:                   PCT Int. Appl., 70 pp.
                          CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003031438	A1	20030417	WO 2002-US32354		20021010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2462950	AA	20030417	CA 2002-2462950		20021010
US 2003130235	A1	20030710	US 2002-268082		20021010
US 6642232	B2	20031104			
EP 1434774	A1	20040707	EP 2002-776202		20021010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002013185	A	20040914	BR 2002-13185		20021010
JP 2005508953	T2	20050407	JP 2003-534421		20021010
PRIORITY APPLN. INFO.:			US 2001-328226P	P	20011010
			WO 2002-US32354	W	20021010

OTHER SOURCE(S): MARPAT 138:304310
ED Entered STN: 18 Apr 2003
GI



I



II

AB Title compds. I [R = H, PO2R5, acyl, alkyl, etc.; R1 = H, alkyl, alkoxy, OH, CF3, etc.; R2 = H, alkyl, heteroaryl, alkoxy, etc.; R3-5 = H, alkyl; A = (un)substituted heterocycloamino; Het = cycloalkylaminoalkyl, heteroaryl, etc.; X = amino, alkoxy; n = 0-1] are prepared For instance, 4-amino-1-benzylpiperidine is converted to 4-(morpholin-4-yl)piperidine (i. DMF, K2CO3, 50°; ii. MeOHaq, H2-Pd/C) and coupled to prior art (Z)-3-(3,5-dimethyl-4-carboxy-1H-pyrrol-2-ylmethylidene)-5-fluoro-1,3-dihydro-2H-indol-2-one (DMF, BOP, Et3N) to give II. I inhibit kinases, in particular VEGFR, PDGFR and c-KIT kinases (no data) and are useful for the treatment of glioblastoma, melanoma, etc.

IT **511295-70-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-[4-(heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivs. as VEGFR and PDGFR kinase inhibitors)

RN 511295-70-8 CAPLUS

CN Piperidine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2003:235017 CAPLUS
DOCUMENT NUMBER: 139:159434
TITLE: Synthesis of Potent Oxindole CDK2 Inhibitors
AUTHOR(S): Dermatakis, Apos; Luk, Kin-Chun; DePinto, Wanda
CORPORATE SOURCE: Hoffmann-La Roche Inc., Nutley, NJ, 07110-1199, USA
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(8), 1873-1881
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:159434
ED Entered STN: 26 Mar 2003
AB A series of oxindole CDK2 inhibitors was synthesized. These novel analogs have a saturated monosubstituted cyclic moiety at their C-4 position that mimics the ribofuranoside of ATP. This substitution afforded agents with increased potency relative to the parent indolinone and nanomolar range IC50 against the CDK2 enzyme and two cancer cell lines.
IT **573704-68-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and structure-activity relationship of potent oxindole CDK2 inhibitors in cancer treatment)
RN 573704-68-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(1H-imidazol-1-yl)-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-nitro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2002:31440 CAPLUS
DOCUMENT NUMBER: 136:102386
TITLE: Preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Wei, Chung Chen; Huang, Ping; Cui, Jingron
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002551	A1	20020110	WO 2001-US20768	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414468	AA	20020110	CA 2001-2414468	20010629
US 2002187978	A1	20021212	US 2001-894902	20010629
US 6635640	B2	20031021		
EP 1296975	A1	20030402	EP 2001-948830	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502686	T2	20040129	JP 2002-507803	20010629
US 2004097497	A1	20040520	US 2003-648810	20030827

PRIORITY APPLN. INFO.:		
US 2000-215654P	P	20000630
US 2001-894902	A3	20010629
WO 2001-US20768	W	20010629

OTHER SOURCE(S): MARPAT 136:102386
ED Entered STN: 11 Jan 2002
GI



I



II

AB Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, etc.; Het = (un)substituted aromatic heterocycle containing at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted aromatic heterocycle containing not more than two N atoms, 5-membered ring (un)substituted heterocycle containing N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.] with some exceptions, were prepared Included are 75 synthetic examples and results for several protein tyrosine kinase assays for those compds. For instance, 4-bromoindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf)•CH2Cl2, 80°C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine•HCl (THF, Pd(PPh3)4, NaOH, 70°C, 6 h) to give the indole which was treated with C5H5N•Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dyhydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 mM for FGFR-1 tyrosine kinase and 0.03 mM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.

IT **388116-44-7P 388116-45-8P 388116-47-0P**
388116-50-5P 388116-51-6P 388116-52-7P
388116-54-9P 388116-55-0P 388116-56-1P
388116-57-2P, 3-(1H-Indol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-58-3P**, 4-(Pyridin-4-yl)-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one **388116-59-4P**, 3-[5-(2-(Morpholin-4-yl)ethoxy)-1H-indol-2-ylmethylene]-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-60-7P**
388116-61-8P 388116-62-9P 388116-64-1P
388116-65-2P 388116-66-3P 388116-68-5P
388116-70-9P, 3-(5-Methylthiophen-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-71-0P**, 3-(4-Morpholin-4-ylbenzylidene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
388116-72-1P 388116-73-2P 388116-74-3P
388116-76-5P 388117-14-4P 388117-16-6P,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-2-yl-1,3-dihydroindol-2-one **388117-17-7P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyrimidin-5-yl-1,3-dihydroindol-2-one **388117-18-8P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-(thiazol-2-yl)-1,3-dihydroindol-2-one **388117-19-9P**
388117-20-2P 388117-21-3P 388117-22-4P,
4-(6-Aminopyridin-3-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one
388117-23-5P 388117-24-6P, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-3-yl-1,3-

dihydroindol-2-one **388117-25-7P 388117-26-8P**, 5-[3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-27-9P**, 5-[3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-28-0P 388117-29-1P**, 4-(2-Aminopyrimidin-5-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one **388117-30-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-44-7 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-45-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-47-0 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-50-5 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-51-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-52-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)



RN 388116-54-9 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-55-0 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-56-1 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-57-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 388116-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-pyridinyl)-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 388116-59-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-indol-2-yl[2-(4-morpholinyl)ethoxy]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-60-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-61-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-62-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[4-(4-morpholinyl)-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)butylidene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-64-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-65-2 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-66-3 CAPLUS
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-68-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388116-70-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-71-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[4-(4-morpholinyl)phenyl]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-72-1 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[4-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 388116-73-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-74-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 388116-76-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-14-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-16-6 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-17-7 CAPLUS

CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-18-8 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-19-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-20-2 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-21-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-22-4 CAPLUS
CN Piperazine, 1-[[5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-

ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-23-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-24-6 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-25-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-26-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-27-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[3-[2-[[2-(diethylamino)ethyl]amino]-1-(3,5-dimethyl-1H-pyrrol-2-yl)-2-oxoethylidene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-28-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-29-1 CAPLUS
CN Piperazine, 1-[[5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **388116-49-2P**, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)
RN 388116-49-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:421132 CAPLUS
DOCUMENT NUMBER: 133:43433
TITLE: Preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases.
INVENTOR(S): Corbett, Wendy Lea; Luk, Kin-chun; Mahaney, Paige E.
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000035909	A1	20000622	WO 1999-EP9673		19991209
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2354591	AA	20000622	CA 1999-2354591		19991209
BR 9916223	A	20010904	BR 1999-16223		19991209
EP 1149093	A1	20011031	EP 1999-966933		19991209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200101858	T2	20011221	TR 2001-200101858		19991209
AU 760039	B2	20030508	AU 2000-22815		19991209
CN 1136216	B	20040128	CN 1999-814585		19991209
US 6307056	B1	20011023	US 1999-464466		19991215
ZA 2001004320	A	20020826	ZA 2001-4320		20010525
PRIORITY APPLN. INFO.:			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209

OTHER SOURCE(S): MARPAT 133:43433
ED Entered STN: 23 Jun 2000
GI



I

AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4,

NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl, etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepared Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (preparation given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100° for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 μM.

IT **276251-34-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276251-34-4 CAPLUS

CN 2H-Indol-2-one, 4-(2,6-dimethoxy-4-pyrimidinyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 8 USPATFULL on STN DUPLICATE 2

ACCESSION NUMBER: 2003:188442 USPATFULL

TITLE: 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors

INVENTOR(S): Mattson, Matthew, Santa Clara, CA, UNITED STATES
Vojkovsky, Tomas, San Mateo, CA, UNITED STATES
Liang, Congxin, Sunnyvale, CA, UNITED STATES
Tang, Peng Cho, Morago, CA, UNITED STATES
Guan, Huiping, Foster City, CA, UNITED STATES

PATENT ASSIGNEE(S): Sugen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003130235	A1	20030710	
	US 6642232	B2	20031104	
APPLICATION INFO.:	US 2002-268082	A1	20021010	(10)

	NUMBER	DATE

Searched by Barb O'Bryen, STIC 2-2518

PRIORITY INFORMATION: US 2001-328226P 20011010 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 2285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to certain 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives that inhibit kinases, in particular VEGFR and/or PDGFR kinases. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **511295-70-8P**
(preparation of 3-[4-(heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivs. as VEGFR and PDGFR kinase inhibitors)
RN 511295-70-8 USPATFULL
CN Piperidine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L9 ANSWER 6 OF 8 USPATFULL on STN DUPLICATE 5
ACCESSION NUMBER: 2002:330293 USPATFULL
TITLE: 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho, Moraga, CA, UNITED STATES
Wei, Chung Chen, Foster City, CA, UNITED STATES
Huang, Ping, Mountain View, CA, UNITED STATES

Cui, Jingrong, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002187978	A1	20021212	
	US 6635640	B2	20031021	
APPLICATION INFO.:	US 2001-894902	A1	20010629	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215654P	20000630 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 4655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases ("PKs"), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **388116-44-7P 388116-45-8P 388116-47-0P 388116-50-5P 388116-51-6P 388116-52-7P 388116-54-9P 388116-55-0P 388116-56-1P 388116-57-2P**, 3-(1H-Indol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-58-3P**, 4-(Pyridin-4-yl)-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one **388116-59-4P**, 3-[5-(2-(Morpholin-4-yl)ethoxy)-1H-indol-2-ylmethylene]-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-60-7P 388116-61-8P 388116-62-9P 388116-64-1P 388116-65-2P 388116-66-3P 388116-68-5P 388116-70-9P**, 3-(5-Methylthiophen-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-71-0P**, 3-(4-Morpholin-4-ylbenzylidene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-72-1P 388116-73-2P 388116-74-3P 388116-76-5P 388117-14-4P 388117-16-6P**, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-2-yl-1,3-dihydroindol-2-one **388117-17-7P**, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyrimidin-5-yl-1,3-dihydroindol-2-one **388117-18-8P**, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-(thiazol-2-yl)-1,3-dihydroindol-2-one **388117-19-9P 388117-20-2P 388117-21-3P 388117-22-4P**, 4-(6-Aminopyridin-3-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one **388117-23-5P 388117-24-6P**, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-3-yl-1,3-dihydroindol-2-one **388117-25-7P 388117-26-8P**, 5-[3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-27-9P**, 5-[3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid

388117-28-0P 388117-29-1P, 4-(2-Aminopyrimidin-5-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one **388117-30-4P**
(drug; preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-44-7 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-45-8 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-47-0 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-50-5 USPATFULL
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-51-6 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-52-7 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)



RN 388116-54-9 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-55-0 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-56-1 USPATFULL
CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-57-2 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 388116-58-3 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-pyridinyl)-3-[(4,5,6,7-tetrahydro-1H-
indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 388116-59-4 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-indol-2-yl[2-(4-
morpholinyl)ethoxy]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-60-7 USPATFULL
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-
indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-61-8 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-62-9 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[4-(4-morpholinyl)-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)butylidene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-64-1 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-65-2 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-66-3 USPATFULL
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-68-5 USPATFULL
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388116-70-9 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-71-0 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[[4-(4-morpholinyl)phenyl]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-72-1 USPATFULL
CN 1-Piperazinecarboxaldehyde, 4-[4-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 388116-73-2 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-74-3 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 388116-76-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-14-4 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-16-6 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-17-7 USPATFULL

CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-18-8 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-19-9 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-20-2 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-21-3 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-22-4 USPATFULL
CN Piperazine, 1-[[5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-

ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-23-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-24-6 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-25-7 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-26-8 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-27-9 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[2-[[2-(diethylamino)ethyl]amino]-1-(3,5-dimethyl-1H-pyrrol-2-yl)-2-oxoethylidene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-28-0 USPATFULL
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-29-1 USPATFULL
CN Piperazine, 1-[[5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **388116-49-2P**, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
(preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)
RN 388116-49-2 USPATFULL
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 7 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2004:127513 USPATFULL
TITLE: 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their

use as protein kinase inhibitors

INVENTOR(S): Tang, Peng Cho, Moraga, CA, UNITED STATES
Wei, Chung Chen, Foster City, CA, UNITED STATES
Huang, Ping, Mountain View, CA, UNITED STATES
Cui, Jingrong, Foster City, CA, UNITED STATES
PATENT ASSIGNEE(S): Sugen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097497	A1	20040520
APPLICATION INFO.:	US 2003-648810	A1	20030827 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-894902, filed on 29 Jun 2001, GRANTED, Pat. No. US 6635640

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215654P	20000630 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 4661

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases ("PKs"), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **388116-44-7P 388116-45-8P 388116-47-0P**
388116-50-5P 388116-51-6P 388116-52-7P
388116-54-9P 388116-55-0P 388116-56-1P
388116-57-2P, 3-(1H-Indol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-58-3P**, 4-(Pyridin-4-yl)-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one **388116-59-4P**, 3-[5-(2-(Morpholin-4-yl)ethoxy)-1H-indol-2-ylmethylene]-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-60-7P**
388116-61-8P 388116-62-9P 388116-64-1P
388116-65-2P 388116-66-3P 388116-68-5P
388116-70-9P, 3-(5-Methylthiophen-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-71-0P**, 3-(4-Morpholin-4-ylbenzylidene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
388116-72-1P 388116-73-2P 388116-74-3P
388116-76-5P 388117-14-4P 388117-16-6P,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-2-yl-1,3-dihydroindol-2-one **388117-17-7P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyrimidin-5-yl-1,3-dihydroindol-2-one **388117-18-8P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-(thiazol-2-yl)-1,3-dihydroindol-2-one **388117-19-9P**
388117-20-2P 388117-21-3P 388117-22-4P,
4-(6-Aminopyridin-3-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one
388117-23-5P 388117-24-6P, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-3-yl-1,3-

dihydroindol-2-one **388117-25-7P 388117-26-8P**, 5-[3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-27-9P**, 5-[3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-28-0P 388117-29-1P**, 4-(2-Aminopyrimidin-5-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one **388117-30-4P**
(drug; preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-44-7 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-45-8 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-47-0 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-50-5 USPATFULL
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-51-6 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-52-7 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)



RN 388116-54-9 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-55-0 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-56-1 USPATFULL
CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-57-2 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 388116-58-3 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-pyridinyl)-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 388116-59-4 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[1H-indol-2-yl[2-(4-morpholinyl)ethoxy]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-60-7 USPATFULL
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-61-8 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-62-9 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[4-(4-morpholinyl)-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)butylidene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-64-1 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-65-2 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-66-3 USPATFULL
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-68-5 USPATFULL
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388116-70-9 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-71-0 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[[4-(4-morpholinyl)phenyl]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-72-1 USPATFULL
CN 1-Piperazinecarboxaldehyde, 4-[4-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 388116-73-2 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-74-3 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 388116-76-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-14-4 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-16-6 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-17-7 USPATFULL

CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-18-8 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-19-9 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-20-2 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-thiazolyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-21-3 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-22-4 USPATFULL
CN Piperazine, 1-[[5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-

ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-23-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-24-6 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-25-7 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-26-8 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-27-9 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[2-[[2-(diethylamino)ethyl]amino]-1-(3,5-dimethyl-1H-pyrrol-2-yl)-2-oxoethylidene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-28-0 USPATFULL
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-29-1 USPATFULL
CN Piperazine, 1-[[5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **388116-49-2P**, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
(preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)
RN 388116-49-2 USPATFULL
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 8 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2001:185487 USPATFULL
TITLE: 4-aryloxindoles

Searched by Barb O'Bryen, STIC 2-2518

INVENTOR(S): Corbett, Wendy Lea, Randolph, NJ, United States
Luk, Kin-Chun, North Caldwell, NJ, United States
Mahaney, Paige E., Montclair, NJ, United States
PATENT ASSIGNEE(S): Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6307056	B1	20011023
APPLICATION INFO.:	US 1999-464466		19991215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112590P	19981217 (60)
	US 1999-149028P	19990816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Johnston, George W., Rocha-Tramaloni, Patricia S.
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 3094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are 4-aryloxindoles that inhibit or modulate protein kinases, in particular JNK protein kinases. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are useful as anti-inflammatory agents, particularly useful in the treatment of rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing the foregoing compounds, as well as methods for the treatment and/or control of inflammation, particularly in the treatment or control of rheumatoid arthritis, using said compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **276251-34-4P**
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)
RN 276251-34-4 USPATFULL
CN 2H-Indol-2-one, 4-(2,6-dimethoxy-4-pyrimidinyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



FILE 'HOME' ENTERED AT 15:51:40 ON 18 AUG 2005

=>

```
=> fil medl cancer drugu pascal biotechno esbio capl confsci biotechds dissabs toxcenter
embase wpids; d que l7;d que l13; s l7 or l13
FILE 'MEDLINE' ENTERED AT 16:12:42 ON 10 FEB 2005

FILE 'CANCERLIT' ENTERED AT 16:12:42 ON 10 FEB 2005

FILE 'DRUGU' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'PASCAL' ENTERED AT 16:12:42 ON 10 FEB 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:12:42 ON 10 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CONFSCI' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'TOXCENTER' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 ACS

FILE 'EMBASE' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:12:42 ON 10 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION
```

inventors search

```
L1          2841 SEA TANG P?/AU
L2          7293 SEA WEI C?/AU
L3          7924 SEA HUANG P?/AU
L4          4065 SEA CUI J?/AU
L7             6 SEA L1 AND L2 AND L3 AND L4
```

```
L1          2841 SEA TANG P?/AU
L2          7293 SEA WEI C?/AU
L3          7924 SEA HUANG P?/AU
L4          4065 SEA CUI J?/AU
L5          2724 SEA INDOLINON?
L6        699113 SEA PROTEIN (2W) KINASE#
L10       131574 SEA L6(3A)(INHIB? OR BLOCK? OR ANTAG?)
L13           31 SEA L5(S) L10 AND (L1 OR L2 OR L3 OR L4)
```

```
L15          34 L7 OR L13

=> dup rem l15
PROCESSING COMPLETED FOR L15
L16          19 DUP REM L15 (15 DUPLICATES REMOVED)
                ANSWERS '1-14' FROM FILE CAPLUS
                ANSWERS '15-16' FROM FILE TOXCENTER
                ANSWERS '17-19' FROM FILE WPIDS

=> d ibib ed abs 1-14; d iall 15-19

L16  ANSWER 1 OF 19  CAPLUS  COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2004:857170  CAPLUS
DOCUMENT NUMBER:          141:350032
TITLE:                    Preparation of 5-sulfonamido-substituted
                          indolinone compounds as protein
                          kinase inhibitors
INVENTOR(S):              Tang, Peng Cho; Liang, Congxin; Miller,
                          Todd; Lipson, Kenneth E.
PATENT ASSIGNEE(S):       Sugen Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 58 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2004204407         A1    20041014    US 2004-793952          20040308
PRIORITY APPLN. INFO.:                       US 2003-452552P     P   20030307
OTHER SOURCE(S):          MARPAT 141:350032
ED   Entered STN:  18 Oct 2004
GI
```



I



II

AB The title compds. [I; R1 and R2 combine to form (un)substituted optionally fused heterocyclic ring; R3-R5 = H, alkyl, hydroxyalkyl, etc.; or R3 and R4 may combine to form a cyclic 6-membered alicyclic ring which may be substituted with one or more lower alkyl] that modulate the activity of protein kinases ("PKs") and are therefore useful in treating disorders related to abnormal PK activity (no biol. data), were prepared General method of synthesis of the compds. I by condensation of oxindoles and aldehydes (preparation of intermediates is given) is described. Eighty-two compds. I (e.g., II) were prepared Pharmaceutical compns. comprising the compds. I, methods of treating diseases utilizing pharmaceutical compns. comprising these compds. and methods of preparing them are also disclosed.

L16 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2002:658111 CAPLUS
DOCUMENT NUMBER: 137:185408
TITLE: 3-(4-Amidopyrrol-2-ylmethylidene)-2-**indolinone** derivatives as **protein kinase inhibitors**
INVENTOR(S): Guan, Huiping; Liang, Congxin; Sun, Li; **Tang, Peng Cho**; **Wei, Chung Chen**; Mauragis, Michael A.; Vojkovsky, Tomas; Jin, Qingwu; Herrinton, Paul Matthew
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066463	A1	20020829	WO 2002-US4407	20020215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2438314	AA	20020829	CA 2002-2438314		20020215
US 2003092917	A1	20030515	US 2002-76140		20020215
US 6653308	B2	20031125			
EP 1370554	A1	20031217	EP 2002-714897		20020215

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EE 200300385	A	20040216	EE 2003-385		20020215
BR 2002007494	A	20040427	BR 2002-7494		20020215
JP 2004522776	T2	20040729	JP 2002-565978		20020215
WO 2003070725	A2	20030828	WO 2003-US4520		20030214
WO 2003070725	A3	20040115			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003229229	A1	20031211	US 2003-367008		20030214
EP 1476443	A2	20041117	EP 2003-742760		20030214

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

NO 2003003608	A	20031014	NO 2003-3608		20030814
US 2004102510	A1	20040527	US 2003-656907		20030908

PRIORITY APPLN. INFO.:			US 2001-268683P	P	20010215
			US 2001-312361P	P	20010815
			US 2002-76140	A3	20020215
			WO 2002-US4407	W	20020215
			US 2002-411732P	P	20020918
			WO 2003-US4520	W	20030214

OTHER SOURCE(S): MARPAT 137:185408
ED Entered STN: 30 Aug 2002
GI



I



II

AB Title compds. I [R1 = H, halo, alkyl, haloalkoxy, cycloalkyl, heterocyclic, OH, alkoxy, (un)esterified CO2H, (un)substituted NH2, CONH2; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (un)substituted NH2, SO2NH2, (un)esterified CO2H, SO2R8, R8 = alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; R3-R6 = H, alkyl; R7 = H, alkyl, aryl, heteroaryl, acyl; Z = aryl, heteroaryl, heterocyclic, (un)substituted NH2] were prepared for use as protein kinase inhibitors in treatment of diseases, such as cancer (no data). Thus, Et 3,5-dimethyl-4-pyrrolecarboxylate was oxidized to the 5-carboxaldehyde, followed by ester hydrolysis, reaction with 5-fluoro-2-oxindole and amidation to give the amide II.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2002:31440 CAPLUS
DOCUMENT NUMBER: 136:102386
TITLE: Preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-**indolinones** and their use as **protein kinase inhibitors**
INVENTOR(S): **Tang, Peng Cho; Wei, Chung Chen; Huang, Ping; Cui, Jingron**
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002551	A1	20020110	WO 2001-US20768	20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2414468	AA	20020110	CA 2001-2414468	20010629
US 2002187978	A1	20021212	US 2001-894902	20010629
US 6635640	B2	20031021		
EP 1296975	A1	20030402	EP 2001-948830	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502686	T2	20040129	JP 2002-507803	20010629
US 2004097497	A1	20040520	US 2003-648810	20030827
PRIORITY APPLN. INFO.:			US 2000-215654P	P 20000630
			US 2001-894902	A3 20010629
			WO 2001-US20768	W 20010629

OTHER SOURCE(S): MARPAT 136:102386
ED Entered STN: 11 Jan 2002
GI



I



II

AB Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, etc.; Het = (un)substituted aromatic heterocycle containing at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted aromatic heterocycle containing not more than two N atoms, 5-membered ring (un)substituted heterocycle containing N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.] with some exceptions, were prepared Included are 75 synthetic examples and results for several protein tyrosine kinase assays for those compds. For instance, 4-bromoindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf)•CH2Cl2, 80°C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine•HCl (THF, Pd(PPh3)4, NaOH, 70°C, 6 h) to give the indole which was treated with C5H5N•Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dyhydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 mM for FGFR-1 tyrosine kinase and 0.03 mM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2002:902261 CAPLUS

DOCUMENT NUMBER: 138:4517
TITLE: Preparation of 3-heteroarylmethylidene-2-**indolinone protein kinase inhibitors** for use against cancer and other disorders
INVENTOR(S): McMahon, Gerald; **Tang, Peng Cho**; Sun, Li
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 64 pp., Cont.-in-part of U.S. Ser. No. 74,621.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6486185	B1	20021126	US 1998-191458	19981112
US 6316429	B1	20011113	US 1998-74621	19980507
US 2002156083	A1	20021024	US 2001-819698	20010329
US 6683082	B2	20040127		
US 2004106630	A1	20040603	US 2003-725079	20031202
US 2004106618	A1	20040603	US 2003-725267	20031202

PRIORITY APPLN. INFO.:

US 1997-45838P	P	19970507
US 1997-59677P	P	19970919
US 1998-74621	A2	19980507
US 2001-819698	A3	20010329

OTHER SOURCE(S): MARPAT 138:4517
ED Entered STN: 27 Nov 2002
GI



I



II



III



IV

AB The present invention relates to novel 3-heteroarylidene-2-indolinone compds. (shown as I; e.g. 3-[3-(2-carboxyethyl)-4-methylpyrrol-2-methylidene]-2-indolinone) and physiol. acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. In I: A, B, D and E = C and N, it being understood that the N-containing 9-member bicyclic ring formed is one known in the chemical arts; it being further understood that when A, B, D, or E is N, R3, R4, R5 or R6, resp., does not exist. R1 = H, alkyl, cycloalkyl, aryl, hydroxy, alkoxy, carboxy, C-amido and sulfonyl; R2 = H, alkyl, cycloalkyl,

aryl, heteroaryl, and heteroalicyclic; R3, R4, R5 and R6 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, -SH, -S-alkyl, -S-cycloalkyl, -S-aryl, -S-heteroaryl, sulfinyl, sulfonyl, sulfonamido, carbonyl, carboxy, cyano, nitro, halo, -OC(O)NR10R11, N-carbamyl, -OC(S)NR10R11, N-thiocarbamyl, C-amido, N-amido, amino and -NR10R11; R10 and R11 = H, alkyl, cycloalkyl, aryl, carbonyl, sulfonyl and, combined, a five- or six-member heteroalicyclic ring containing at least one N; R3 and R4, R4 and R5, or R4 and R5 may combine to form a six-member aryl or heteroaryl ring. Q is a heteroaryl group II in which J = O, N and S; K, L and M = C, N, O and S such that the five-member heteroaryl ring formed is one known in the chemical arts, it being understood that when K, L and M are N, S or O, R8 or -(alk1)nZ cannot be covalently bonded to that atom; when J is N, R7 = H, alkyl, cycloalkyl, aryl, hydroxy, alkoxy, aryloxy, carbonyl, carboxy, C-amido, guanyl and sulfonyl and when J is O or S, R7 does not exist and there is no bond; R8 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, -SH, -S-alkyl, -S-cycloalkyl, -S-aryl, -S-heteroaryl, sulfinyl, sulfonyl, sulfonamido, carbonyl, carboxy, cyano, nitro, halo, -OC(O)NR10R11, N-carbamyl, -OC(S)NR10R11, N-thiocarbamyl, C-amido, N-amido, amino, -NR10R11, trihalomethyl, a five member cycloalkyl, aryl, heteroaryl or heteroalicyclic ring fused to two adjacent atoms of the Q ring; and a six-member cycloalkyl, aryl, heteroaryl, or heteroalicyclic ring fused to two adjacent atoms of the Q ring. R10and R11 = H, alkyl, cycloalkyl, aryl, carbonyl, sulfonyl and, combined, a five- or six-member heteroalicyclic ring containing at least one N; alk1 = optionally substituted methylene (-CRR'-), optionally substituted ethylene (-C(R):C(R')-) and acetylene (-C.tplbond.C-); R and R' = H, alkyl, cycloalkyl, aryl, alkoxy, -S-alkyl, -S-cycloalkyl, aryloxy and halo. N is 0 to 10, inclusive with the proviso that when n is 0, R7 is not alkyl substituted with aryl; and Z is a polar group hydroxy, alkoxy, carboxy, nitro, cyano, carbamyl, amino, quaternary ammonium, amido, ureido, sulfonamido, sulfinyl, sulfonyl, phosphono, phosphonyl, morpholino, piperazinyl and tetrazolo. Also claimed are a combinatorial library of ≥13 I and a method for synthesizing I comprising the step of reacting III with a 2nd reactant IV in a solvent and in the presence of a base at elevated temps. The IC50 results for 12 I for PDGFR, FLK-1R, EGFR, HER2 and IGF-1R protein tyrosine kinases (PTKs) are presented; IC50 refers to that amount of the tested compound needed to effect a 50% inhibition of PTK activity in the test indicated with respect to a control in which no compound of this invention is present. Thus, 3-(2,4-dimethyl-3-ethoxycarbonylpyrrol-5-methylidenyl)-2-indolinone inhibited FLK-IR kinase with IC50 = 0.07 μM.

REFERENCE COUNT: 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2001:904107 CAPLUS
DOCUMENT NUMBER: 136:37505
TITLE: Preparation of 3-(2-indolylmethylene)-2-**indolinones** as **protein kinase**/phosphatase **inhibitors** for treatment of proliferative diseases
INVENTOR(S): **Tang, Peng Cho**; Harris, G. Davis; Li, Xiaoyuan
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094312	A2	20011213	WO 2001-US17961	20010604
WO 2001094312	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2410509	AA	20011213	CA 2001-2410509	20010604
US 2002052369	A1	20020502	US 2001-871700	20010604
US 6706709	B2	20040316		
EP 1294688	A2	20030326	EP 2001-946059	20010604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003535847	T2	20031202	JP 2002-501862	20010604
US 2004147586	A1	20040729	US 2003-725277	20031202
PRIORITY APPLN. INFO.:			US 2000-209162P	P 20000602
			US 2001-871700	A3 20010604
			WO 2001-US17961	W 20010604

OTHER SOURCE(S): MARPAT 136:37505
ED Entered STN: 14 Dec 2001
GI



I



II

AB Title compds. I [wherein R4-R6 and R8-R10 = H; R1, R2, and R3 = independently H, halo, carboxylic acid, trihalomethyl, or (un)substituted ester, amide, alkyl, alkoxy, or (hetero)aryl; R7 = (un)substituted alkyl or alkoxy; or pharmaceutically acceptable salt thereof] were prepared as modulators of the activity of protein kinases (PKs) and phosphatases. For example, 5-bromo-2-oxindole was coupled with 5-(3-diethylaminopropyl)-1H-indole-2-carbaldehyde (preparation given) in the presence of piperidine in EtOH

to afford II, which inhibited GST-FLK-1, EGF receptor kinase, and PDGF with IC50 values of 0.03 μM, 2.87 μM, and 0.38 μM, resp. I are useful in treating disorders related to abnormal PK activity, such as blood vessel proliferative disorders, mesangial cell proliferative disorders, fibrotic disorders, cancer, diabetes, autoimmune disorders, hyperproliferation disorders, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, inflammatory disorders, immunol. disorders, and cardiovascular disorders (no data). Combinatorial libraries comprising at least five indolinone compds., formed by reacting oxindoles with aldehydes, are also claimed.

L16 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2001:661426 CAPLUS
DOCUMENT NUMBER: 135:226880
TITLE: Synthesis of Pyrolyllactone-indolinone derivatives as kinase inhibitors
INVENTOR(S): **Tang, Peng Cho**; Miller, Todd A.; Li, Xiaoyuan; Zhang, Ruofei; **Cui, Jingrong**; **Huang, Ping**; **Wei, Chung Chen**
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064681	A2	20010907	WO 2001-US6214	20010228
WO 2001064681	A3	20020418		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2400649	AA	20010907	CA 2001-2400649	20010228
US 2002042427	A1	20020411	US 2001-794957	20010228
US 6465507	B2	20021015		
EP 1259514	A2	20021127	EP 2001-913094	20010228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525296	T2	20030826	JP 2001-564178	20010228

PRIORITY APPLN. INFO.: US 2000-185536P P 20000228
WO 2001-US6214 W 20010228

OTHER SOURCE(S): MARPAT 135:226880
ED Entered STN: 10 Sep 2001
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl, (hetero)aromatic ring, (hetero)aliphatic ring, etc.; R2-5 = H, alkyl, (hetero)aromatic ring, (hetero)aliphatic ring; A, B, D, E = C or N provided that one or two = N and provided that when A, B, D or E = N, no R1 is attached to A, B, D or E; m = 2 - 4; q = 1 - 4] were prepared

Examples include data for over 50 compds. synthesized and over 20 bioassays (data for 4 bioassays provided). For instance, tosylmethyl isocyanide was added to 5,6-dihydro-2H-pyran-2-one (DBU, THF, 0°C, room temperature, 2 h.) to give 6,7-dihydro-2H-pyrano[3,4-c]pyrrol-4-one. This intermediate was formylated in the 1-position (DMF, POCl3, DCM, room temperature, 1 h.) followed by condensation of the 1-formyl derivative with 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid N-Me amide to yield II. II had IC50 = 0.005 mM for cdk2/cyclin A and IC50 = 6.64 mM for GST-Flk1. Compds. II are used to treat cancer, e.g., squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, etc.

L16 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2001:617993 CAPLUS
DOCUMENT NUMBER: 135:195497
TITLE: Preparation of pyrrole substituted 2-**indolinone protein kinase inhibitors** for treatment of cancer
INVENTOR(S): **Tang, Peng Cho**; Miller, Todd; Li, Xiaoyuan; Sun, Li; **Wei, Chung Chen**; Shirazian, Shahrzad; Liang, Congxin; Vojkovsky, Tomas; Nematalla, Asaad S.
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060814	A2	20010823	WO 2001-US4813	20010215
WO 2001060814	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2399358	AA	20010823	CA 2001-2399358	20010215
US 2002156292	A1	20021024	US 2001-783264	20010215
US 6573293	B2	20030603		
EP 1255752	A2	20021113	EP 2001-914376	20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523340	T2	20030805	JP 2001-560198	20010215
BR 2001008394	A	20040622	BR 2001-8394	20010215
NO 2002003831	A	20021015	NO 2002-3831	20020813
ZA 2002006469	A	20031113	ZA 2002-6469	20020813
BG 107078	A	20030430	BG 2002-107078	20020910
US 2004063773	A1	20040401	US 2003-412690	20030414

PRIORITY APPLN. INFO.:	US 2000-182710P	P	20000215
	US 2000-216422P	P	20000706
	US 2000-243532P	P	20001027
	US 2001-783264	A3	20010215
	WO 2001-US4813	W	20010215

OTHER SOURCE(S): MARPAT 135:195497
ED Entered STN: 24 Aug 2001
GI



I



II

AB The title compds. (I) [wherein R1 = H, halo, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, OH, alkoxy, acyl, (un)substituted amino or carbamoyl, etc.; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (hetero)aryl, (un)substituted amino, acyl(amino), or sulfamoyl, etc.; R3 = H, halo, alkyl, trihalomethyl, OH, alkoxy, (hetero)aryl, (un)substituted acyl, (acyl)amino, sulfamoyl, or alkylsulfonyl, etc.; R4 = H, halo, alkyl, OH, alkoxy, or (un)substituted amino; R5 and R6 = independently H, alkyl, or acyl; R7 = H, alkyl, (hetero)aryl, or acyl; and their pharmaceutically acceptable salts] were prepared as protein kinase modulators for the treatment of cellular disorders such as cancer. For example, 5-fluoro-1,3-dihydroindol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give II (55%). II exhibited comparable activity against Flk-1 and PDGFRβ and inhibited PDGF-dependent receptor phosphorylation in cells with an IC50 value of approx. 0.03 μM. In efficacy expts. against various cancers in mice, II was well tolerated at 80 mg/kg/day, even when dosed continuously for more than 100 days.

L16 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 8
ACCESSION NUMBER: 2001:830898 CAPLUS
DOCUMENT NUMBER: 135:357926
TITLE: Synthesis of indolinone vinyl-derivatives used to modulate protein kinase activity
INVENTOR(S): **Tang, Peng Cho**; Sun, Li; Mcmahon, Gerald; Harris, G. David
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: U.S., 29 pp., Cont.-in-part of U.S. Ser. No. 212,494.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 6316635	B1	20011113	US 1999-293518	19990415
US 5880141	A	19990309	US 1995-485323	19950607
US 5792783	A	19980811	US 1996-655223	19960605
US 5883113	A	19990316	US 1996-659191	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A2	20000125	JP 1999-159567	19960605
US 6225335	B1	20010501	US 1998-212494	19981215
US 2001027207	A1	20011004	US 2001-765619	20010122
US 6469032	B2	20021022		
US 2002028840	A1	20020307	US 2001-899550	20010706
US 6569868	B2	20030527		
US 2003191128	A1	20031009	US 2003-372341	20030225

PRIORITY APPLN. INFO.:

US 1995-485323	A2	19950607
US 1995-485323	A2	19950607
US 1996-655223	A2	19960605
US 1996-659191	A1	19960605
US 1998-82056P	P	19980416
US 1998-212494	A2	19981215
EP 1996-918093	A3	19960605
JP 1997-501363	A3	19960605
US 1999-293518	A1	19990415
US 2001-899550	A3	20010706

OTHER SOURCE(S): MARPAT 135:357926
ED Entered STN: 15 Nov 2001
GI



I



II

AB Title compds. I [G, J = N such that, when G = N, J = C and when J = N, G = C, it being recognized that, when G or J = N, R5 or R5' does not exist; R1-3 = H; R4, R5, R5' H, alk(en/yn)yl, cycloalkyl, aryl, heteroaryl, heteroalicylic, halo, hydroxy, nitro, cyano, alkoxy, aryloxy, etc.; R6-9 =

H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, etc.] with some exceptions, were prepared For instance, 2-ethyl-4-formylimidazole was reacted with resin bound 2-chlorotriphenylmethyl chloride (CH2Cl2, iPr2NEt, 21 h, room temperature) and the isolated product condensed with 2-indolinone (DMF, piperidine, 80°C, 20 h) to give the corresponding resin-bound 2-indolinone. The resin bound intermediate was cleaved (CH2Cl2, TFA, 2 h, room temperature) to give II as the TFA salt of a 10:1 E/Z mixture I exhibit kinase inhibitory activity and are useful for treating, e.g., diabetes, autoimmune disorder, etc.

REFERENCE COUNT: 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 9
ACCESSION NUMBER: 2000:688215 CAPLUS
DOCUMENT NUMBER: 133:252306
TITLE: Preparation of **indolinones** as **protein kinase inhibitors.**
INVENTOR(S): **Tang, Peng Cho**; Sun, Li; Mcmahon, Gerald; Miller, Todd Anthony; Shirazian, Shahrzad; **Wei, Chung Chen**; Harris, G. Davis; Xiaoyuan, Li; Liang, Congxin
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056709	A1	20000928	WO 2000-US7704	20000322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368041	AA	20000928	CA 2000-2368041	20000322
EP 1165513	A1	20020102	EP 2000-916622	20000322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002540096	T2	20021126	JP 2000-606571	20000322
US 6689806	B1	20040210	US 2000-534405	20000322

PRIORITY APPLN. INFO.:

US 1999-125945P	P	19990324
US 1999-127863P	P	19990405
US 1999-131192P	P	19990426
US 1999-132243P	P	19990503
WO 2000-US7704	W	20000322

OTHER SOURCE(S): MARPAT 133:252306
ED Entered STN: 29 Sep 2000
GI



I

AB Title compds., e.g. [I; m, n = 0, 1; Q = (JR11)m; Q1 = (DR6)n; when n = 1, then A, B, D, E, F = C, N; ≤3 of A, B, D, E, F = N; when m = 1, then G, H, J, K, L = C, N; ≥1 and ≤3 of G, H, J, K, L = N; when n = 0, then A = C, N, B, F = C, N, NH, O, S; E = C, N, O, S; when m = O, then G = C, N, H, K, l = C, N, NH, O, S; R1-R13 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, SH, alkylthiol, aryloxy, amino, etc.; R4R5 or R5R6 or R6R7 or R7R8 = atoms to form a 5-6 membered (hetero)aryl ring; with addnl. provisos], were prepared Thus, 6-pyridin-3-yl-1,3-dihydroindol-2-one (preparation given), 4-methoxy-3-thien-2-ylbenzaldehyde, and piperidine were refluxed overnight in EtOH to give 15% 3-(4-methoxy-3-thien-2-ylbenzylidene)-6-pyridin-3-yl-1,3-dihydroindol-2-one. Tested title compds. inhibited HER2 kinase with IC50 = 16.4 μM to ≥100 μM.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 10

ACCESSION NUMBER: 2000:622463 CAPLUS

DOCUMENT NUMBER: 133:217719

TITLE: 3-(Cyclohexanoheteroarylidenyl)-2-**indolinone** **protein** tyrosine **kinase** **inhibitors**, and their therapeutic use

INVENTOR(S): **Tang, Peng Cho**; Sun, Li; McMahon, Gerald; Blake, Robert A.

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: U.S., 61 pp., Cont. -in-part of U.S. Ser. No. 99,842. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6114371	A	20000905	US 1998-190970	19981112
US 6130238	A	20001010	US 1998-99842	19980619
US 2002183370	A1	20021205	US 2001-29946	20011231
US 6579897	B2	20030617		

PRIORITY APPLN. INFO.:

US 1997-50977P	P	19970620
US 1997-59384P	P	19970919
US 1998-99842	A2	19980619
US 1997-50413P	P	19970620
US 1997-59544P	P	19970919
US 1998-99721	A1	19980619
US 2000-482198	A3	20000112

OTHER SOURCE(S): CASREACT 133:217719; MARPAT 133:217719

ED Entered STN: 07 Sep 2000
AB 3-(Cyclohexano-heteroarylidenyl)-2-indolinone compds., and physiol. acceptable salts and prodrugs thereof, are disclosed which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase-related cellular disorders (cancer, arthritis, restenosis, etc.).
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 11
ACCESSION NUMBER: 1999:764021 CAPLUS
DOCUMENT NUMBER: 132:12257
TITLE: Preparation of pyrrole substituted 2-**indolinone protein kinase inhibitors**
INVENTOR(S): **Tang, Peng Cho**; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 240 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961422	A1	19991202	WO 1999-US12069	19990528
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2314156	AA	19991202	CA 1999-2314156	19990528
AU 9944102	A1	19991213	AU 1999-44102	19990528
AU 759226	B2	20030410		
EP 1082305	A1	20010314	EP 1999-927120	19990528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9910792	A	20020129	BR 1999-10792	19990528
TR 200003514	T2	20020521	TR 2000-200003514	19990528
US 6395734	B1	20020528	US 1999-322297	19990528
JP 2002516310	T2	20020604	JP 2000-550828	19990528
NO 2000005916	A	20010129	NO 2000-5916	20001122
US 2003105151	A1	20030605	US 2002-81147	20020225

PRIORITY APPLN. INFO.:

US 1998-87310P	P	19980529
US 1999-116106P	P	19990115
US 1999-322297	A1	19990528
WO 1999-US12069	W	19990528

OTHER SOURCE(S): MARPAT 132:12257
ED Entered STN: 03 Dec 1999
GI



I



II

AB The present invention relates to 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid derivs. (I) [where R1 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, aryl, OH, alkoxy, carboxy, acetyl, (thio)amido, (trihalomethane)sulfonyl, etc.; R2 = H, halo, (cyclo)alkyl, (hetero)aryl, or heteroalicyclic; R3, R4, R5, R6, R8, R9, R10 = independently H, (cyclo)alkyl, trihaloalkyl, alkenyl, alkynyl, (hetero)aryl(oxy), heteroalicyclic, OH, alkoxy, SH, alkylthio, arylthio, sulfinyl, sulfonyl, sulfonamido , carbonyl, carboxy, amido, CN, NO2, halo, (thio)carbamyl, (un)substituted amino, etc.] which modulate the activity of protein kinases and are useful in the prevention and treatment of protein kinase related cellular disorders, such as cancer. Thus, 2,4-dimethyl-5-ethoxycarbonyl-3-(2-ethoxycarbonylethyl)pyrrole was deprotected using NaOH to form 3-(2-carboxyethyl)-2,4-dimethylpyrrole (100%) and the product C-5 formylated (two methods given for 86% and 90% yield, resp.). Reaction with 2-oxindole in EtOH and pyrrolidine or in aqueous NaOH yielded II (88% and 91%, resp.), which reduced the average size of C6 human glioma and melanoma tumors s.c. implanted in mice by 80-85%. II, when administered orally, demonstrated notably superior efficacy compared to structurally similar analogs.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:170636 CAPLUS
DOCUMENT NUMBER: 138:337929
TITLE: Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase
AUTHOR(S): Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; **Cui, Jean**; Fukuda, Juri Y.; Chu, Ji-Yu; Nemataalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho
CORPORATE SOURCE: SUGEN Inc., South San Francisco, CA, 94080, USA

SOURCE: Journal of Medicinal Chemistry (2003), 46(7), 1116-1119
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:337929
ED Entered STN: 07 Mar 2003
GI



I

AB To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized. Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, solubility, protein binding, and bioavailability. II is currently in phase I clin. trials for the treatment of cancers.
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:868415 CAPLUS
DOCUMENT NUMBER: 136:697
TITLE: Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
INVENTOR(S): Moon, Malcolm Wilson; Morozowich, Walter; Gao, Ping; **Tang, Peng Cho**
PATENT ASSIGNEE(S): Sugen, Inc., USA; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090068	A2	20011129	WO 2001-US16757	20010524
WO 2001090068	A3	20020606		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2408709	AA	20011129	CA 2001-2408709	20010524
AU 2001064885	A5	20011203	AU 2001-64885	20010524
US 2002032204	A1	20020314	US 2001-863804	20010524
US 6710067	B2	20040323		
US 2002035140	A1	20020321	US 2001-863905	20010524
US 6451838	B2	20020917		
US 2002037878	A1	20020328	US 2001-863819	20010524
US 6482848	B2	20021119		
EP 1301507	A2	20030416	EP 2001-939357	20010524
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003534323	T2	20031118	JP 2001-586257	20010524
US 2003045565	A1	20030306	US 2002-243663	20020916
US 2003083363	A1	20030501	US 2002-243942	20020916
US 6716870	B2	20040406		
US 2004127542	A1	20040701	US 2003-429895	20030505
US 2004127544	A1	20040701	US 2003-743909	20031224

PRIORITY APPLN. INFO.:	US 2000-207000P	P	20000524
	US 2000-225045P	P	20000811
	US 2001-863804	A1	20010524
	US 2001-863819	A3	20010524
	US 2001-863905	A1	20010524
	WO 2001-US16757	W	20010524
	US 2002-243663	B1	20020916

OTHER SOURCE(S): MARPAT 136:697
ED Entered STN: 30 Nov 2001
AB The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. that modulate the activity of protein kinases ("PKs"). Pharmaceutical compns. comprising these compds., methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compns. comprising these compds. and methods of preparing them are also disclosed.

L16 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:147306 CAPLUS
DOCUMENT NUMBER: 128:204803
TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Hirth, Klaus Peter; Shawver, Laura Kay; et al.
PATENT ASSIGNEE(S): Sugen, Inc., USA; Tang, Peng Cho; Sun, Li; McMahon, Gerald
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807695	A1	19980226	WO 1997-US14736	19970820
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CN 1155838	A	19970730	CN 1996-190616		19960605
CA 2264220	AA	19980226	CA 1997-2264220		19970820
EP 929520	A1	19990721	EP 1997-939480		19970820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2001503736	T2	20010321	JP 1998-510973		19970820
EP 1247803	A2	20021009	EP 2002-77564		19970820
EP 1247803	A3	20021016			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
AU 9741556	A1	19980306	AU 1997-41556		19970821
PRIORITY APPLN. INFO.:			US 1996-702232	A	19960823
			US 1996-31585P	P	19961205
			US 1996-31586P	P	19961205
			US 1996-31588P	P	19961205
			US 1996-32546P	P	19961205
			US 1996-32547P	P	19961205
			US 1997-45565P	P	19970505
			US 1997-45566P	P	19970505
			US 1997-45714P	P	19970505
			US 1997-45715P	P	19970505
			US 1997-46843P	P	19970505
			EP 1997-939480	A3	19970820
			WO 1997-US14736	W	19970820

OTHER SOURCE(S): MARPAT 128:204803
ED Entered STN: 11 Mar 1998
GI



I

AB The invention relates to indolinone derivs. capable of modulating, regulating, and/or inhibiting protein kinase signal transduction. The compds. are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis, and restenosis, and metabolic diseases such as diabetes. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of the indole ring. Indolinone compds. that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano[b]pyrrole moiety. Indolinone compds. that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosol. indolinone compds. that are tyrosine kinase inhibitors, and related products and methods. Approx. 1200 title compds.,

such as I, were prepared by combinatorial condensation of certain (un)substituted indolinones with aldehydes at the 3-position. I gave complete inhibition of MET kinase at chimeric MET receptors in vitro.
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 15 OF 19 TOXCENTER COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:227676 TOXCENTER
COPYRIGHT: Copyright 2005 ACS
DOCUMENT NUMBER: CA14118295860J
TITLE: Preparation of hexahydro-cyclohepta[b]pyrrole oxindole as potent kinase inhibitors
AUTHOR(S): **Tang, Peng Cho**; Xia, Yi; Hawtin, Rachael
CORPORATE SOURCE: ASSIGNEE: Sugen, Inc.
PATENT INFORMATION: US 2004186160 A1 23 Sep 2004
SOURCE: (2004) U.S. Pat. Appl. Publ., 60 pp.
CODEN: USXXCO.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2004:780367
LANGUAGE: English
ENTRY DATE: Entered STN: 20041014
Last Updated on STN: 20041229

ABSTRACT:
Indolinone compds., hexahydro-cyclohepta[b]pyrrole oxindoles of formula I [R1, R2 = H, alkyl, cycloalkyl, aryl, etc.; R3-R6 = H, halo, alkyl, cycloalkyl, alkoxy, aryl, aryloxy, heteroaryl, etc.; R7 = H, alkyl, cycloalkyl, aryl, OH, CN, etc.; R8 = H, alkyl, cycloalkyl, aryl, hydroxyalkylene, etc.; R9 = H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; p = 1-2], are prepared which are useful as **protein kinase inhibitors.**
Thus, II was prepared from 3-(3-dimethylaminopropyl)-1,4,5,6,7,8-hexahydro-cyclohepta[b]pyrrole-2-carbaldehyde (preparation given) and 2-oxindole.
CLASSIFICATION CODE: 27-11
SUPPLEMENTARY TERMS: Miscellaneous Descriptors
oxindole cycloheptapyrrole prepn protein kinase inhibitor
REGISTRY NUMBER: 372092-80-3 (Protein kinase)
80449-02-1 (Tyrosine kinase)
137632-09-8 (HER-2 kinase)
141349-86-2 (CDK2 kinase)
59-48-3 (2-Oxindole)
83-41-0 (3-Nitro-o-xylene)
98-80-6 (Benzeneboronic acid)
110-91-8 (Morpholine)
254-04-6 (Benzopyran)
364-73-8 (5-Bromo-2-fluoronitrobenzene)
443-69-6 (5-Fluoroisatin)
1073-06-9 (3-Bromofluorobenzene)
1194-18-9 (1,3-Cycloheptanedione)
2038-03-1 (4-(2-Aminoethyl)morpholine)
5451-09-2 (5-Aminolevulinic acid hydrochloride)
14794-31-1 (Ethyl succinyl chloride)
17630-75-0 (5-Chloro-2-oxindole)
20443-98-5 (2,6-Dichlorobenzyl bromide)
388116-27-6 (4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole)
6127-11-3 (4-Bromo-2-nitrophenylacetic acid)
7699-18-5 (5-Methoxy-2-oxindole)
7699-19-6 (6-Methoxy-2-oxindole)

13220-46-7 (4-Methyl-2-oxindole)
20870-78-4 (5-Bromo-2-oxindole)
20876-30-6 (4-Methoxy-2-nitrophenylacetic acid)
23876-18-8 (2-Methyl-6-nitrophenylacetic acid)
39755-95-8 (5-Methoxyisatin)
56341-41-4 (5-Fluoro-2-oxindole)
80726-56-3 (3-Nitrobiphenyl-4-acetic acid)
90750-91-7 (5-Phenyl-2-oxindole)
90751-00-1 (6-Phenyl-2-oxindole)
99365-40-9 (6-Bromo-2-oxindole)
170565-89-6 (5-Dimethylaminosulfonyl-2-oxindole)
175075-24-8 (5-Aminosulfonyl-2-oxindole)
199328-31-9 (5-Chlorosulfonyl-2-oxindole)
199328-55-7 (5-Methylaminosulfonyl-2-oxindole)
206879-57-4 (4-Fluoro-3-nitrobiphenyl)
356068-89-8 ((2-Amino-5-fluorophenyl)acetic acid hydrazide)

REGISTRY NUMBER: 760997-72-6; 760997-73-7; 760997-43-1; 760997-44-2; 760997-45-3; 760997-46-4; 760997-47-5; 760997-48-6; 760997-49-7; 760997-50-0; 760997-51-1; 760997-52-2; 760997-53-3; 760997-54-4; 760997-55-5; 760997-56-6; 760997-57-7; 760997-58-8; 760997-59-9; 760997-60-2; 760997-61-3; 760997-62-4; 760997-63-5; 760997-64-6; 760997-65-7; 760997-66-8; 760997-67-9; 760997-68-0; 760997-69-1; 760997-70-4; 760997-71-5; 760997-74-8; 760997-75-9; 760997-76-0; 760997-77-1; 760997-78-2; 760997-79-3; 760997-80-6; 760997-81-7; 760997-82-8; 760997-83-9; 760997-84-0; 760997-85-1; 760997-86-2; 760997-87-3; 760997-88-4; 760997-89-5; 760997-90-8; 760997-91-9; 760997-92-0; 760997-93-1; 760997-94-2; 760997-95-3; 760997-96-4; 760997-97-5; 760997-98-6; 760997-99-7; 760998-00-3; 760998-01-4; 760998-02-5; 760998-03-6; 760998-04-7; 760998-05-8; 760998-06-9; 760998-07-0; 760998-08-1; 760998-09-2; 760998-10-5; 760998-11-6; 760998-12-7; 760998-13-8; 760998-14-9; 760998-15-0; 760998-16-1; 760998-17-2; 760998-18-3; 104-94-9; 7182-08-3; 10298-80-3; 51207-66-0; 258831-98-0; 477573-08-3; 760998-24-1; 10565-15-8; 139122-15-9; 139122-16-0; 139122-17-1; 139122-19-3; 168476-58-2; 199327-88-3; 442562-62-1; 442562-88-1; 477573-39-0; 502156-97-0; 502156-99-2; 760998-19-4; 760998-20-7; 760998-21-8; 760998-22-9; 760998-26-3; 760998-28-5; 760998-29-6; 760998-30-9; 760998-31-0

L16 ANSWER 16 OF 19 TOXCENTER COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:119314 TOXCENTER
COPYRIGHT: Copyright 2005 ACS
DOCUMENT NUMBER: CA12817204803K
TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease
AUTHOR(S): **Tang, Peng Cho**; Sun, Li; McMahon, Gerald; Hirth, Klaus Peter; Shawver, Laura Kay; et al.
CORPORATE SOURCE: ASSIGNEE: McMahon, Gerald
PATENT INFORMATION: WO 987695 A1 26 Feb 1998
SOURCE: (1998) PCT Int. Appl., 293 pp.
CODEN: PIXXD2.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1998:147306
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116

Last Updated on STN: 20020605

ABSTRACT:
The invention relates to **indolinone** derivs. capable of modulating, regulating, and/or **inhibiting protein kinase** signal transduction. The compds. are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis, and restenosis, and metabolic diseases such as diabetes. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of the indole ring. Indolinone compds. that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano[b]pyrrole moiety. Indolinone compds. that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosol. indolinone compds. that are tyrosine kinase inhibitors, and related products and methods. Approx. 1200 title compds., such as I, were prepared by combinatorial condensation of certain (un)substituted indolinones with aldehydes at the 3-position. I gave complete inhibition of MET kinase at chimeric MET receptors in vitro.

CLASSIFICATION CODE: 27-11

SUPPLEMENTARY TERMS: Miscellaneous Descriptors
indolinone combinatorial library **protein kinase inhibitor**; antiproliferative
indolinone prepn combinatorial library

REGISTRY NUMBER: 9026-43-1 (Protein kinase)
80449-02-1 (Tyrosine kinase)
137632-03-2 (MET kinase)
2199-58-8 (3,5-Dimethylpyrrole-2-carboxaldehyde)
13220-46-7 (4-Methyl-2-oxindole)
20870-78-4 (5-Bromo-2-oxindole)
20870-79-5 (5-Nitro-2-oxindole)
20876-36-2 (5-Amino-2-oxindole)
23876-18-8 ((2-Methyl-6-nitrophenyl)acetic acid)
56341-41-4 (5-Fluoro-2-oxindole)
65435-04-3 (5-(Chloroacetyl)-2-oxindole)
99017-95-5 (Ethyl 3,5-diethylpyrrole-2-carboxylate)
102359-00-2 (5-Carboxy-2-oxindole)
118306-76-6 (5-(2-Chloroethyl)-2-oxindole)
199328-10-4 (5-(Methoxycarbonyl)-2-oxindole)
204002-18-6 (5-(2-Carboxyethyl)-2-oxindole)
204002-19-7 (5-(2-Cyanoethyl)-2-oxindole)
101700-45-2 (3-[(2-Nitrofuran-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203988-27-6 (3-(2-Ethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203988-29-8 (3-[(Thien-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203988-31-2 (3-[(1-Methylpyrrol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203988-33-4 (3-(4-Fluorobenzylidenyl)-5,7-dibromo-2-indolinone)
203988-35-6 (3-[(Indol-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203988-36-7 (3-[(2-Methylthien-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203988-37-8 (3-(4-Bromobenzylidenyl)-5,7-dibromo-2-indolinone)
203988-38-9 (3-[(Pyrrol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203988-39-0 (3-(2-Hydroxy-6-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)

203988-42-5 (3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203988-44-7 (3-(2-Ethoxybenzylidenyl)-5-iodo-2-indolinone)
203988-46-9 (3-[(Thien-2-yl)methylidenyl]-5-iodo-2-indolinone)
203988-47-0 (3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-iodo-2-indolinone)
203988-48-1 (3-(4-Fluorobenzylidenyl)-5-iodo-2-indolinone)
203988-49-2 (3-[(Indol-3-yl)methylidenyl]-5-iodo-2-indolinone)
203988-50-5 (3-[(2-Methylthien-5-yl)methylidenyl]-5-iodo-2-indolinone)
203988-51-6 (3-(4-Bromobenzylidenyl)-5-iodo-2-indolinone)
203988-52-7 (3-[(Pyrrol-2-yl)methylidenyl]-5-iodo-2-indolinone)
203988-53-8 (3-(2-Hydroxy-6-methoxybenzylidenyl)-5-iodo-2-indolinone)
203988-54-9 (3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone)
203988-55-0 (3-(2-Ethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203988-56-1 (3-[(Thien-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203988-57-2 (3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203988-58-3 (3-(4-Fluorobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203988-59-4 (3-[(Indol-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203988-60-7 (3-[(2-Methylthien-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203988-61-8 (3-(4-Bromobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203988-62-9 (3-[(Pyrrol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203988-63-0 (3-(2-Hydroxy-6-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203988-64-1 (3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203988-65-2 (3-(2-Ethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203988-66-3 (3-[(Thien-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203988-67-4 (3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203988-68-5 (3-(4-Fluorobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203988-69-6 (3-[(Indol-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203988-70-9 (3-[(2-Methylthien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203988-71-0 (3-(4-Bromobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203988-72-1 (3-[(Pyrrol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203988-73-2 (3-(2-Hydroxy-6-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203988-74-3 (3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203988-75-4 (3-(2-Ethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-76-5 (3-[(Thien-2-yl)methylidenyl]-5-[[[4-

(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-77-6 (3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-78-7 (3-(4-Fluorobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-79-8 (3-[(Indol-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-80-1 (3-[(2-Methylthien-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-81-2 (3-(4-Bromobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-82-3 (3-[(Pyrrol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-83-4 (3-(2-Hydroxy-6-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-84-5 (3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203988-85-6 (3-(2-Ethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203988-86-7 (3-[(Thien-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203988-87-8 (3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203988-88-9 (3-(4-Fluorobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203988-89-0 (3-[(Indol-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203988-90-3 (3-[(2-Methylthien-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203988-91-4 (3-(4-Bromobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203988-92-5 (3-[(Pyrrol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203988-93-6 (3-(2-Hydroxy-6-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203988-94-7 (3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203988-95-8 (3-(2-Ethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203988-96-9 (3-[(Thien-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203988-97-0 (3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203988-98-1 (3-(4-Fluorobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203988-99-2 (3-[(Indol-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-00-8 (3-[(2-Methylthien-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-01-9 (3-(4-Bromobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203989-02-0 (3-[(Pyrrol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-03-1 (3-(2-Hydroxy-6-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203989-04-2 (3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-05-3 (3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203989-06-4 (3-(3-Bromo-2-hydroxy-5-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)

203989-07-5 (3-[(1-Hydroxynaphth-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203989-08-6 (3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203989-09-7 (3-[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203989-10-0 (3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203989-11-1 (3-(4-Chloro-3-nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
203989-12-2 (3-(2,4-Dihydroxy-3-methylbenzylidenyl)-5,7-dibromo-2-indolinone)
203989-13-3 (3-(Furan-2-ylmethylidenyl)-5,7-dibromo-2-indolinone)
203989-14-4 (3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone)
203989-15-5 (3-(3-Bromo-2-hydroxy-5-methoxybenzylidenyl)-5-iodo-2-indolinone)
203989-16-6 (3-[(1-Hydroxynaphth-2-yl)methylidenyl]-5-iodo-2-indolinone)
203989-17-7 (3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone)
203989-18-8 (3-[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl]methylidenyl]-5-iodo-2-indolinone)
203989-19-9 (3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-iodo-2-indolinone)
203989-20-2 (3-(4-Chloro-3-nitrobenzylidenyl)-5-iodo-2-indolinone)
203989-21-3 (3-(2,4-Dihydroxy-3-methylbenzylidenyl)-5-iodo-2-indolinone)
203989-22-4 (3-(Furan-2-ylmethylidenyl)-5-iodo-2-indolinone)
203989-23-5 (3-[(2-Nitrofuran-5-yl)methylidenyl]-5-iodo-2-indolinone)
203989-24-6 (3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203989-25-7 (3-(3-Bromo-2-hydroxy-5-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203989-26-8 (3-[(1-Hydroxynaphth-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203989-27-9 (3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203989-28-0 (3-[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203989-29-1 (3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203989-30-4 (3-(4-Chloro-3-nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203989-31-5 (3-(2,4-Dihydroxy-3-methylbenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203989-32-6 (3-(Furan-2-ylmethylidenyl)-5-bromo-4-methyl-2-indolinone)
203989-33-7 (3-[(2-Nitrofuran-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203989-35-9 (3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203989-36-0 (3-(3-Bromo-2-hydroxy-5-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203989-38-2 (3-[(1-Hydroxynaphth-2-yl)methylidenyl]-5-

[(methylamino)sulfonyl]-2-indolinone)
203989-40-6 (3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203989-42-8 (3-[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203989-43-9 (3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203989-45-1 (3-(4-Chloro-3-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203989-46-2 (3-(2,4-Dihydroxy-3-methylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203989-48-4 (3-(Furan-2-ylmethylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203989-49-5 (3-[(2-Nitrofuran-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203989-52-0 (3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-53-1 (3-(3-Bromo-2-hydroxy-5-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-55-3 (3-[(1-Hydroxynaphth-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-56-4 (3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-57-5 (3-[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-58-6 (3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-60-0 (3-(4-Chloro-3-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-61-1 (3-(2,4-Dihydroxy-3-methylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-62-2 (3-(Furan-2-ylmethylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-64-4 (3-[(2-Nitrofuran-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203989-65-5 (3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203989-66-6 (3-(3-Bromo-2-hydroxy-5-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203989-67-7 (3-[(1-Hydroxynaphth-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203989-68-8 (3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203989-69-9 (3-[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203989-70-2 (3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203989-71-3 (3-(4-Chloro-3-nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203989-72-4 (3-(2,4-Dihydroxy-3-methylbenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203989-73-5 (3-(Furan-2-ylmethylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203989-74-6 (3-[(2-Nitrofuran-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)

203989-75-7 (3-[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-76-8 (3-(3-Bromo-2-hydroxy-5-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203989-77-9 (3-[(1-Hydroxynaphth-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-78-0 (3-[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-79-1 (3-[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-80-4 (3-[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-81-5 (3-(4-Chloro-3-nitrobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203989-82-6 (3-(2,4-Dihydroxy-3-methylbenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203989-83-7 (3-(Furan-2-ylmethylidenyl)-5-(2-chloroethyl)-2-indolinone)
203989-84-8 (3-[(2-Nitrofuran-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203989-85-9 (3-(4-Ethoxy-3-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203989-86-0 (3-(3,4-Dihydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203989-87-1 (3-(2,4-Dimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203989-88-2 (3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203989-89-3 (3-(2,4,6-Trimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203989-90-6 (3-(4-Hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203989-91-7 (3-[4-(Dimethylamino)benzylidenyl]-5,7-dibromo-2-indolinone)
203989-92-8 (3-(2-Chloro-4-fluorobenzylidenyl)-5,7-dibromo-2-indolinone)
203989-93-9 (3-(3-Nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
203989-94-0 (3-[4-Fluoro-2-(trifluoromethyl)benzylidenyl]-5,7-dibromo-2-indolinone)
203989-95-1 (3-(4-Ethoxy-3-methoxybenzylidenyl)-5-iodo-2-indolinone)
203989-96-2 (3-(3,4-Dihydroxybenzylidenyl)-5-iodo-2-indolinone)
203989-97-3 (3-(2,4-Dimethoxybenzylidenyl)-5-iodo-2-indolinone)
203989-98-4 (3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone)
203989-99-5 (3-(2,4,6-Trimethoxybenzylidenyl)-5-iodo-2-indolinone)
203990-00-5 (3-(4-Hydroxybenzylidenyl)-5-iodo-2-indolinone)
203990-01-6 (3-[4-(Dimethylamino)benzylidenyl]-5-iodo-2-indolinone)
203990-02-7 (3-(2-Chloro-4-fluorobenzylidenyl)-5-iodo-2-indolinone)
203990-03-8 (3-(3-Nitrobenzylidenyl)-5-iodo-2-indolinone)
203990-04-9 (3-[4-Fluoro-2-(trifluoromethyl)benzylidenyl]-5-iodo-2-indolinone)
203990-05-0 (3-(4-Ethoxy-3-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)

203990-06-1 (3-(3,4-Dihydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-07-2 (3-(2,4-Dimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-08-3 (3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203990-09-4 (3-(2,4,6-Trimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-10-7 (3-(4-Hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-11-8 (3-[4-(Dimethylamino)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203990-12-9 (3-(2-Chloro-4-fluorobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-13-0 (3-(3-Nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-14-1 (3-[4-Fluoro-2-(trifluoromethyl)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203990-15-2 (3-(4-Ethoxy-3-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-16-3 (3-(3,4-Dihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-17-4 (3-(2,4-Dimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-18-5 (3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203990-19-6 (3-(2,4,6-Trimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-20-9 (3-(4-Hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-21-0 (3-[4-(Dimethylamino)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203990-22-1 (3-(2-Chloro-4-fluorobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-23-2 (3-(3-Nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-24-3 (3-[4-Fluoro-2-(trifluoromethyl)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203990-25-4 (3-(4-Ethoxy-3-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-26-5 (3-(3,4-Dihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-27-6 (3-(2,4-Dimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-28-7 (3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-29-8 (3-(2,4,6-Trimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-30-1 (3-(4-Hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-31-2 (3-[4-(Dimethylamino)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-32-3 (3-(2-Chloro-4-fluorobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-33-4 (3-(3-Nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-34-5 (3-[4-Fluoro-2-(trifluoromethyl)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-35-6 (3-(4-Ethoxy-3-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)

203990-36-7 (3-(3,4-Dihydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203990-37-8 (3-(2,4-Dimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203990-38-9 (3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203990-39-0 (3-(2,4,6-Trimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203990-40-3 (3-(4-Hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203990-41-4 (3-[4-(Dimethylamino)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203990-42-5 (3-(2-Chloro-4-fluorobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203990-43-6 (3-(3-Nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203990-44-7 (3-[4-Fluoro-2-(trifluoromethyl)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203990-45-8 (3-(4-Ethoxy-3-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203990-46-9 (3-(3,4-Dihydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203990-47-0 (3-(2,4-Dimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203990-48-1 (3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203990-49-2 (3-(2,4,6-Trimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203990-50-5 (3-(4-Hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203990-51-6 (3-[4-(Dimethylamino)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203990-52-7 (3-(2-Chloro-4-fluorobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203990-53-8 (3-(3-Nitrobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203990-54-9 (3-[4-Fluoro-2-(trifluoromethyl)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203990-55-0 (3-(2,4,6-Trifluorobenzylidenyl)-5,7-dibromo-2-indolinone)
203990-56-1 (3-(4-Hydroxy-2-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203990-57-2 (3-(3,4-Dimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203990-58-3 (3-(2-Hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203990-59-4 (3-(Benzylidenyl)-5,7-dibromo-2-indolinone)
203990-60-7 (3-[[2-(Methylthio)thien-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203990-61-8 (3-(2,4-Dihydroxy-6-methylbenzylidenyl)-5,7-dibromo-2-indolinone)
203990-62-9 (3-(3-Ethoxy-4-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203990-63-0 (3-(2-Hydroxy-5-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203990-64-1 (3-[(Imidazol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203990-65-2 (3-(2,4,6-Trifluorobenzylidenyl)-5-iodo-2-indolinone)
203990-66-3 (3-(4-Hydroxy-2-methoxybenzylidenyl)-5-iodo-2-indolinone)
203990-67-4 (3-(3,4-Dimethoxybenzylidenyl)-5-iodo-2-

indolinone)
REGISTRY NUMBER: 203990-68-5 (3-(2-Hydroxybenzylidenyl)-5-iodo-2-indolinone)
203990-69-6 (3-(Benzylidenyl)-5-iodo-2-indolinone)
203990-70-9 (3-[[2-(Methylthio)thien-5-yl)methylidenyl]-5-iodo-2-indolinone)
203990-71-0 (3-(2,4-Dihydroxy-6-methylbenzylidenyl)-5-iodo-2-indolinone)
203990-72-1 (3-(3-Ethoxy-4-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203990-73-2 (3-(2-Hydroxy-5-methoxybenzylidenyl)-5-iodo-2-indolinone)
203990-74-3 (3-[(Imidazol-2-yl)methylidenyl]-5-iodo-2-indolinone)
203990-75-4 (3-(2,4,6-Trifluorobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-76-5 (3-(4-Hydroxy-2-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-77-6 (3-(3,4-Dimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-78-7 (3-(2-Hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-79-8 (3-(Benzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-80-1 (3-[[2-(Methylthio)thien-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203990-81-2 (3-(2,4-Dihydroxy-6-methylbenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-82-3 (3-(3-Ethoxy-4-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-83-4 (3-(2-Hydroxy-5-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203990-84-5 (3-[(Imidazol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203990-85-6 (3-(2,4,6-Trifluorobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-86-7 (3-(4-Hydroxy-2-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-87-8 (3-(3,4-Dimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-88-9 (3-(2-Hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-89-0 (3-(Benzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-90-3 (3-[[2-(Methylthio)thien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203990-91-4 (3-(2,4-Dihydroxy-6-methylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-92-5 (3-(3-Ethoxy-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-93-6 (3-(2-Hydroxy-5-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203990-94-7 (3-[(Imidazol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203990-96-9 (3-(2,4,6-Trifluorobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203990-98-1 (3-(4-Hydroxy-2-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-00-8 (3-(3,4-Dimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-02-0 (3-(2-Hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)

203991-04-2 (3-(Benzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-05-3 (3-[[2-(Methylthio)thien-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-07-5 (3-(2,4-Dihydroxy-6-methylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-10-0 (3-(3-Ethoxy-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-13-3 (3-(2-Hydroxy-5-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-16-6 (3-[(Imidazol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-20-2 (3-(2,4,6-Trifluorobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203991-23-5 (3-(4-Hydroxy-2-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203991-27-9 (3-(3,4-Dimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203991-31-5 (3-(2-Hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203991-32-6 (3-(Benzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203991-33-7 (3-[[2-(Methylthio)thien-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203991-34-8 (3-(2,4-Dihydroxy-6-methylbenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203991-35-9 (3-(3-Ethoxy-4-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203991-37-1 (3-(2-Hydroxy-5-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203991-39-3 (3-[(Imidazol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203991-41-7 (3-(2,4,6-Trifluorobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203991-43-9 (3-(4-Hydroxy-2-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203991-45-1 (3-(3,4-Dimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203991-47-3 (3-(2-Hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203991-49-5 (3-(Benzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203991-51-9 (3-[[2-(Methylthio)thien-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203991-52-0 (3-(2,4-Dihydroxy-6-methylbenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203991-53-1 (3-(3-Ethoxy-4-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203991-54-2 (3-(2-Hydroxy-5-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203991-55-3 (3-[(Imidazol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203991-56-4 (3-[(1-Methylbenzimidazol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203991-57-5 (3-[(4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203991-58-6 (3-[(2,3-Dimethylthien-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203991-59-7 (3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203991-60-0 (3-[3-(Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl]-5,7-dibromo-2-indolinone)

203991-61-1 (3-[(2-Chlorothien-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203991-62-2 (3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203991-63-3 (3-(3-tert-Butyl-4-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203991-64-4 (3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203991-65-5 (3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203991-66-6 (3-[(1-Methylbenzimidazol-2-yl)methylidenyl]-5-iodo-2-indolinone)
203991-67-7 (3-[(4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-iodo-2-indolinone)
203991-68-8 (3-[(2,3-Dimethylthien-5-yl)methylidenyl]-5-iodo-2-indolinone)
203991-69-9 (3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-iodo-2-indolinone)
203991-70-2 (3-[3-(Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl]-5-iodo-2-indolinone)
203991-71-3 (3-[(2-Chlorothien-5-yl)methylidenyl]-5-iodo-2-indolinone)
203991-72-4 (3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone)
203991-73-5 (3-(3-tert-Butyl-4-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203991-74-6 (3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203991-75-7 (3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203991-76-8 (3-[(1-Methylbenzimidazol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203991-77-9 (3-[(4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203991-78-0 (3-[(2,3-Dimethylthien-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203991-79-1 (3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203991-80-4 (3-[3-(Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl]-5-bromo-4-methyl-2-indolinone)
203991-81-5 (3-[(2-Chlorothien-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203991-82-6 (3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203991-83-7 (3-(3-tert-Butyl-4-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203991-84-8 (3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203991-85-9 (3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203991-86-0 (3-[(1-Methylbenzimidazol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203991-87-1 (3-[(4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203991-88-2 (3-[(2,3-Dimethylthien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203991-89-3 (3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203991-90-6 (3-[3-(Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203991-91-7 (3-[(2-Chlorothien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)

203991-92-8 (3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203991-93-9 (3-(3-tert-Butyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203991-94-0 (3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203991-95-1 (3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203991-96-2 (3-[(1-Methylbenzimidazol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-97-3 (3-[(4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-98-4 (3-[(2,3-Dimethylthien-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203991-99-5 (3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-00-1 (3-[3-(Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-01-2 (3-[(2-Chlorothien-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-02-3 (3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-03-4 (3-(3-tert-Butyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-04-5 (3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-05-6 (3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-06-7 (3-[(1-Methylbenzimidazol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-07-8 (3-[(4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-08-9 (3-[(2,3-Dimethylthien-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-09-0 (3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-10-3 (3-[3-(Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-11-4 (3-[(2-Chlorothien-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-12-5 (3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-13-6 (3-(3-tert-Butyl-4-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203992-14-7 (3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203992-15-8 (3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203992-16-9 (3-[(1-Methylbenzimidazol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-17-0 (3-[(4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-18-1 (3-[(2,3-Dimethylthien-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-19-2 (3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-20-5 (3-[3-(Chloromethyl)-2-hydroxy-5-

nitrobenzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-21-6 (3-[(2-Chlorothien-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-22-7 (3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-23-8 (3-(3-tert-Butyl-4-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-24-9 (3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-25-0 (3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-26-1 (3-(3-tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
203992-27-2 (3-(2,4,6-Trihydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203992-28-3 (3-[(2-Nitrothien-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203992-29-4 (3-(4-Carboxybenzylidenyl)-5,7-dibromo-2-indolinone)
203992-30-7 (3-(2,4-Difluorobenzylidenyl)-5,7-dibromo-2-indolinone)
203992-31-8 (3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203992-32-9 (3-(3-tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203992-33-0 (3-[(2-Nitrothien-4-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203992-34-1 (3-[4-(Di-n-butylamino)benzylidenyl]-5,7-dibromo-2-indolinone)
203992-35-2 (3-[4-(Trifluoromethyl)benzylidenyl]-5,7-dibromo-2-indolinone)
203992-36-3 (3-(3-tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-iodo-2-indolinone)
203992-37-4 (3-(2,4,6-Trihydroxybenzylidenyl)-5-iodo-2-indolinone)
203992-38-5 (3-[(2-Nitrothien-5-yl)methylidenyl]-5-iodo-2-indolinone)
203992-39-6 (3-(4-Carboxybenzylidenyl)-5-iodo-2-indolinone)
203992-40-9 (3-(2,4-Difluorobenzylidenyl)-5-iodo-2-indolinone)
203992-41-0 (3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203992-42-1 (3-(3-tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203992-43-2 (3-[(2-Nitrothien-4-yl)methylidenyl]-5-iodo-2-indolinone)
203992-44-3 (3-[4-(Di-n-butylamino)benzylidenyl]-5-iodo-2-indolinone)
203992-45-4 (3-[4-(Trifluoromethyl)benzylidenyl]-5-iodo-2-indolinone)
203992-46-5 (3-(3-tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203992-47-6 (3-(2,4,6-Trihydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203992-48-7 (3-[(2-Nitrothien-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203992-49-8 (3-(4-Carboxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203992-50-1 (3-(2,4-Difluorobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203992-51-2 (3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-

bromo-4-methyl-2-indolinone)
203992-52-3 (3-(3-tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203992-53-4 (3-[(2-Nitrothien-4-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203992-54-5 (3-[4-(Di-n-butylamino)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203992-55-6 (3-[4-(Trifluoromethyl)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203992-56-7 (3-(3-tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203992-57-8 (3-(2,4,6-Trihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203992-58-9 (3-[(2-Nitrothien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203992-59-0 (3-(4-Carboxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203992-60-3 (3-(2,4-Difluorobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203992-61-4 (3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203992-62-5 (3-(3-tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203992-63-6 (3-[(2-Nitrothien-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203992-64-7 (3-[4-(Di-n-butylamino)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203992-65-8 (3-[4-(Trifluoromethyl)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203992-66-9 (3-(3-tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-67-0 (3-(2,4,6-Trihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-68-1 (3-[(2-Nitrothien-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-69-2 (3-(4-Carboxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-70-5 (3-(2,4-Difluorobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-71-6 (3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-72-7 (3-(3-tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-73-8 (3-[(2-Nitrothien-4-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-74-9 (3-[4-(Di-n-butylamino)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-75-0 (3-[4-(Trifluoromethyl)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203992-76-1 (3-(3-tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203992-77-2 (3-(2,4,6-Trihydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203992-78-3 (3-[(2-Nitrothien-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-79-4 (3-(4-Carboxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203992-80-7 (3-(2,4-Difluorobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)

Searched by Barb O'Bryen, STIC 2-2518

203992-81-8 (3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203992-82-9 (3-(3-tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203992-83-0 (3-[(2-Nitrothien-4-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-84-1 (3-[4-(Di-n-butylamino)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-85-2 (3-[4-(Trifluoromethyl)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203992-86-3 (3-(3-tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-87-4 (3-(2,4,6-Trihydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-88-5 (3-[(2-Nitrothien-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-89-6 (3-(4-Carboxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-90-9 (3-(2,4-Difluorobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-91-0 (3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-92-1 (3-(3-tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203992-93-2 (3-[(2-Nitrothien-4-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-94-3 (3-[4-(Di-n-butylamino)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-95-4 (3-[4-(Trifluoromethyl)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203992-96-5 (3-(2,3,4-Trihydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203992-97-6 (3-(2-Hydroxy-3-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203992-98-7 (3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203992-99-8 (3-(3,4-Diacetoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203993-00-4 (3-(4-Hydroxy-3-methylbenzylidenyl)-5,7-dibromo-2-indolinone)
203993-01-5 (3-(2-Bromobenzylidenyl)-5,7-dibromo-2-indolinone)
203993-02-6 (3-(2,4-Dihydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203993-03-7 (3-(2-Hydroxy-4-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203993-04-8 (3-(3-Bromobenzylidenyl)-5,7-dibromo-2-indolinone)
203993-05-9 (3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203993-06-0 (3-(2,3,4-Trihydroxybenzylidenyl)-5-iodo-2-indolinone)
203993-07-1 (3-(2-Hydroxy-3-methoxybenzylidenyl)-5-iodo-2-indolinone)
203993-08-2 (3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-iodo-2-indolinone)
203993-09-3 (3-(3,4-Diacetoxybenzylidenyl)-5-iodo-2-indolinone)
203993-10-6 (3-(4-Hydroxy-3-methylbenzylidenyl)-5-iodo-2-indolinone)
203993-11-7 (3-(2-Bromobenzylidenyl)-5-iodo-2-indolinone)
203993-12-8 (3-(2,4-Dihydroxybenzylidenyl)-5-iodo-2-

indolinone)
203993-13-9 (3-(2-Hydroxy-4-methoxybenzylidenyl)-5-iodo-2-indolinone)
203993-14-0 (3-(3-Bromobenzylidenyl)-5-iodo-2-indolinone)
203993-15-1 (3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203993-16-2 (3-(2,3,4-Trihydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-17-3 (3-(2-Hydroxy-3-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-18-4 (3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-19-5 (3-(3,4-Diacetoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-20-8 (3-(2-Bromobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-21-9 (3-(2,4-Dihydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-22-0 (3-(2-Hydroxy-4-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-23-1 (3-(3-Bromobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-24-2 (3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-25-3 (3-(2,3,4-Trihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-26-4 (3-(2-Hydroxy-3-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-27-5 (3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-28-6 (3-(3,4-Diacetoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-29-7 (3-(4-Hydroxy-3-methylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-30-0 (3-(2-Bromobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-31-1 (3-(2,4-Dihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-32-2 (3-(2-Hydroxy-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-33-3 (3-(3-Bromobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-34-4 (3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-35-5 (3-(2,3,4-Trihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203993-36-6 (3-(2-Hydroxy-3-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203993-37-7 (3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203993-38-8 (3-(3,4-Diacetoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)

REGISTRY NUMBER:

203993-39-9 (3-(4-Hydroxy-3-methylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203993-40-2 (3-(2-Bromobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203993-41-3 (3-(2,4-Dihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203993-42-4 (3-(2-Hydroxy-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203993-43-5 (3-(3-Bromobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)

203993-44-6 (3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203993-45-7 (3-(2,3,4-Trihydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-46-8 (3-(2-Hydroxy-3-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-47-9 (3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-48-0 (3-(3,4-Diacetoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-49-1 (3-(4-Hydroxy-3-methylbenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-50-4 (3-(2-Bromobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-51-5 (3-(2,4-Dihydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-52-6 (3-(2-Hydroxy-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-53-7 (3-(3-Bromobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-54-8 (3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203993-55-9 (3-(2,3,4-Trihydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-56-0 (3-(2-Hydroxy-3-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-57-1 (3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-58-2 (3-(3,4-Diacetoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-59-3 (3-(4-Hydroxy-3-methylbenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-60-6 (3-(2-Bromobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-61-7 (3-(2,4-Dihydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-62-8 (3-(2-Hydroxy-4-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-63-9 (3-(3-Bromobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-64-0 (3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203993-65-1 (3-[[1-(Dimethylamino)naphth-4-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203993-66-2 (3-(4-Hydroxy-3-nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
203993-67-3 (3-(3-Hydroxy-4-nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
203993-68-4 (3-[(8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203993-69-5 (3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203993-70-8 (3-[(Benzo[b]furan-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203993-71-9 (3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203993-72-0 (3-[(2-Ethylfuran-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203993-73-1 (3-[(3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203993-74-2 (3-[[1-(Dimethylamino)naphth-4-

yl)methylidenyl]-5-iodo-2-indolinone)
203993-75-3 (3-(4-Hydroxy-3-nitrobenzylidenyl)-5-iodo-2-indolinone)
203993-76-4 (3-(3-Hydroxy-4-nitrobenzylidenyl)-5-iodo-2-indolinone)
203993-77-5 (3-[(8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)methylidenyl]-5-iodo-2-indolinone)
203993-78-6 (3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203993-79-7 (3-[(Benzo[b]furan-2-yl)methylidenyl]-5-iodo-2-indolinone)
203993-80-0 (3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-iodo-2-indolinone)
203993-81-1 (3-[(2-Ethylfuran-5-yl)methylidenyl]-5-iodo-2-indolinone)
203993-82-2 (3-[(3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-iodo-2-indolinone)
203993-83-3 (3-[[1-(Dimethylamino)naphth-4-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203993-84-4 (3-(4-Hydroxy-3-nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-85-5 (3-(3-Hydroxy-4-nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-86-6 (3-[(8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203993-87-7 (3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203993-88-8 (3-[(Benzo[b]furan-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203993-89-9 (3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203993-90-2 (3-[(2-Ethylfuran-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203993-91-3 (3-[(3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203993-92-4 (3-[[1-(Dimethylamino)naphth-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203993-93-5 (3-(4-Hydroxy-3-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-94-6 (3-(3-Hydroxy-4-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-95-7 (3-[(8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203993-96-8 (3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203993-97-9 (3-[(Benzo[b]furan-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203993-98-0 (3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203993-99-1 (3-[(2-Ethylfuran-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-00-7 (3-[(3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-01-8 (3-[[1-(Dimethylamino)naphth-4-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-02-9 (3-(4-Hydroxy-3-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-03-0 (3-(3-Hydroxy-4-nitrobenzylidenyl)-5-[[[4-

(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-04-1 (3-[(8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-05-2 (3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-06-3 (3-[(Benzo[b]furan-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-07-4 (3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-08-5 (3-[(2-Ethylfuran-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-09-6 (3-[(3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-10-9 (3-[[1-(Dimethylamino)naphth-4-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203994-11-0 (3-(4-Hydroxy-3-nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203994-12-1 (3-(3-Hydroxy-4-nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203994-13-2 (3-[(8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203994-14-3 (3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203994-15-4 (3-[(Benzo[b]furan-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203994-16-5 (3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203994-17-6 (3-[(2-Ethylfuran-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203994-18-7 (3-[(3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203994-19-8 (3-[[1-(Dimethylamino)naphth-4-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203994-20-1 (3-(4-Hydroxy-3-nitrobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203994-21-2 (3-(3-Hydroxy-4-nitrobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203994-22-3 (3-[(8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203994-23-4 (3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203994-24-5 (3-[(Benzo[b]furan-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203994-25-6 (3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203994-26-7 (3-[(2-Ethylfuran-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203994-27-8 (3-[(3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203994-28-9 (3-[(3-Bromothien-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203994-29-0 (3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203994-30-3 (3-[(2-Methylfuran-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203994-31-4 (3-[(3-Methylpyrazol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)

203994-32-5 (3-(2-Hydroxy-6-methoxy-4-methylbenzylidenyl)-5,7-dibromo-2-indolinone)
203994-33-6 (3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-5,7-dibromo-2-indolinone)
203994-34-7 (3-[4-(Morpholino)benzylidenyl]-5,7-dibromo-2-indolinone)
203994-35-8 (3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203994-36-9 (3-[[4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203994-37-0 (3-[(Imidazol-4-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203994-39-2 (3-[(3-Bromothien-2-yl)methylidenyl]-5-iodo-2-indolinone)
203994-41-6 (3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5-iodo-2-indolinone)
203994-43-8 (3-[(2-Methylfuran-5-yl)methylidenyl]-5-iodo-2-indolinone)
203994-45-0 (3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-iodo-2-indolinone)
203994-47-2 (3-(2-Hydroxy-6-methoxy-4-methylbenzylidenyl)-5-iodo-2-indolinone)
203994-49-4 (3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-5-iodo-2-indolinone)
203994-51-8 (3-[4-(Morpholino)benzylidenyl]-5-iodo-2-indolinone)
203994-53-0 (3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone)
203994-55-2 (3-[[4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl]methylidenyl]-5-iodo-2-indolinone)
203994-57-4 (3-[(Imidazol-4-yl)methylidenyl]-5-iodo-2-indolinone)
203994-59-6 (3-[(3-Bromothien-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203994-61-0 (3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203994-63-2 (3-[(2-Methylfuran-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203994-65-4 (3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203994-67-6 (3-(2-Hydroxy-6-methoxy-4-methylbenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203994-69-8 (3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203994-70-1 (3-[4-(Morpholino)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203994-72-3 (3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203994-74-5 (3-[[4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203994-75-6 (3-[(Imidazol-4-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203994-77-8 (3-[(3-Bromothien-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-79-0 (3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203994-81-4 (3-[(2-Methylfuran-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-83-6 (3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-

[(methylamino)sulfonyl]-2-indolinone)
203994-85-8 (3-(2-Hydroxy-6-methoxy-4-methylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203994-87-0 (3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-89-2 (3-[4-(Morpholino)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-91-6 (3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-93-8 (3-[[4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-95-0 (3-[(Imidazol-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203994-97-2 (3-[(3-Bromothien-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203994-99-4 (3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-01-1 (3-[(2-Methylfuran-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-03-3 (3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-05-5 (3-(2-Hydroxy-6-methoxy-4-methylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-07-7 (3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-09-9 (3-[4-(Morpholino)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-11-3 (3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-13-5 (3-[[4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-15-7 (3-[(Imidazol-4-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-17-9 (3-[(3-Bromothien-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-19-1 (3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203995-21-5 (3-[(2-Methylfuran-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-22-6 (3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-23-7 (3-(2-Hydroxy-6-methoxy-4-methylbenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203995-24-8 (3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-25-9 (3-[4-(Morpholino)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-26-0 (3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-27-1 (3-[[4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-28-2 (3-[(Imidazol-4-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-29-3 (3-[(3-Bromothien-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-30-6 (3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)

203995-31-7 (3-[(2-Methylfuran-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-32-8 (3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-33-9 (3-(2-Hydroxy-6-methoxy-4-methylbenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203995-34-0 (3-[4-(4-Formylpiperazin-1-yl)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-35-1 (3-[4-(Morpholino)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-36-2 (3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-37-3 (3-[[4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-38-4 (3-[(Imidazol-4-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-39-5 (3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203995-40-8 (3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5,7-dibromo-2-indolinone)
203995-41-9 (3-[(2-Bromofuran-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203995-42-0 (3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203995-43-1 (3-[(5,8-Dihydroxy-1,2,3,4-tetrahydronaphth-6-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203995-46-4 (3-[(2-Ethylthien-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203995-47-5 (3-(4-Methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203995-48-6 (3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone)
203995-49-7 (3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5-iodo-2-indolinone)
203995-50-0 (3-[(2-Bromofuran-5-yl)methylidenyl]-5-iodo-2-indolinone)
203995-51-1 (3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-iodo-2-indolinone)
203995-52-2 (3-[(5,8-Dihydroxy-1,2,3,4-tetrahydronaphth-6-yl)methylidenyl]-5-iodo-2-indolinone)
203995-55-5 (3-[(2-Ethylthien-5-yl)methylidenyl]-5-iodo-2-indolinone)
203995-56-6 (3-(4-Methoxybenzylidenyl)-5-iodo-2-indolinone)
203995-57-7 (3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203995-58-8 (3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203995-59-9 (3-[(2-Bromofuran-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203995-60-2 (3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203995-61-3 (3-[(5,8-Dihydroxy-1,2,3,4-tetrahydronaphth-6-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203995-64-6 (3-[(2-Ethylthien-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203995-65-7 (3-(4-Methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203995-66-8 (3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-

2-indolinone)
203995-67-9 (3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203995-68-0 (3-[(2-Bromofuran-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203995-69-1 (3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203995-70-4 (3-[(5,8-Dihydroxy-1,2,3,4-tetrahydronaphth-6-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203995-73-7 (3-[(2-Ethylthien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203995-74-8 (3-(4-Methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203995-75-9 (3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-76-0 (3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-77-1 (3-[(2-Bromofuran-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-78-2 (3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-79-3 (3-[(5,8-Dihydroxy-1,2,3,4-tetrahydronaphth-6-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-82-8 (3-[(2-Ethylthien-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-83-9 (3-(4-Methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203995-84-0 (3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-85-1 (3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203995-86-2 (3-[(2-Bromofuran-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-87-3 (3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-88-4 (3-[(5,8-Dihydroxy-1,2,3,4-tetrahydronaphth-6-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-91-9 (3-[(2-Ethylthien-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203995-92-0 (3-(4-Methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203995-93-1 (3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-94-2 (3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203995-95-3 (3-[(2-Bromofuran-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-96-4 (3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203995-97-5 (3-[(5,8-Dihydroxy-1,2,3,4-tetrahydronaphth-6-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203996-00-3 (3-[(2-Ethylthien-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203996-01-4 (3-(4-Methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203996-02-5 (3-[4-(Diethylamino)benzylidenyl]-5,7-dibromo-

2-indolinone)
203996-03-6 (3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203996-04-7 (3-(3-Bromo-5-chloro-2-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203996-05-8 (3-[2-[(4-Chlorophenyl)thio]benzylidenyl]-5,7-dibromo-2-indolinone)
203996-06-9 (3-[(5-Chlorobenzodioxolan-6-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203996-07-0 (3-[(1,4-Benzopyranon-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203996-08-1 (3-(3-Cyanobenzylidenyl)-5,7-dibromo-2-indolinone)
203996-09-2 (3-(4-Cyanobenzylidenyl)-5,7-dibromo-2-indolinone)
203996-10-5 (3-(2,5-Dihydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
203996-11-6 (3-(2,3-Dimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203996-12-7 (3-[4-(Diethylamino)benzylidenyl]-5-iodo-2-indolinone)
203996-13-8 (3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone)
203996-14-9 (3-(3-Bromo-5-chloro-2-hydroxybenzylidenyl)-5-iodo-2-indolinone)
203996-15-0 (3-[2-[(4-Chlorophenyl)thio]benzylidenyl]-5-iodo-2-indolinone)
203996-16-1 (3-[(5-Chlorobenzodioxolan-6-yl)methylidenyl]-5-iodo-2-indolinone)
203996-17-2 (3-[(1,4-Benzopyranon-3-yl)methylidenyl]-5-iodo-2-indolinone)
203996-18-3 (3-(3-Cyanobenzylidenyl)-5-iodo-2-indolinone)
203996-19-4 (3-(4-Cyanobenzylidenyl)-5-iodo-2-indolinone)
203996-20-7 (3-(2,5-Dihydroxybenzylidenyl)-5-iodo-2-indolinone)
203996-21-8 (3-(2,3-Dimethoxybenzylidenyl)-5-iodo-2-indolinone)
203996-22-9 (3-[4-(Diethylamino)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203996-23-0 (3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203996-24-1 (3-(3-Bromo-5-chloro-2-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203996-25-2 (3-[2-[(4-Chlorophenyl)thio]benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203996-26-3 (3-[(5-Chlorobenzodioxolan-6-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203996-27-4 (3-[(1,4-Benzopyranon-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203996-28-5 (3-(3-Cyanobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203996-29-6 (3-(4-Cyanobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203996-30-9 (3-(2,5-Dihydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203996-31-0 (3-(2,3-Dimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203996-32-1 (3-[4-(Diethylamino)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203996-33-2 (3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)

REGISTRY NUMBER: 203996-34-3 (3-(3-Bromo-5-chloro-2-hydroxybenzylidenyl)-5-

[(methylamino)sulfonyl]-2-indolinone)
203996-35-4 (3-[2-[(4-Chlorophenyl)thio]benzylidenyl]-5-
[(methylamino)sulfonyl]-2-indolinone)
203996-36-5 (3-[(5-Chlorobenzodioxolan-6-yl)methylidenyl]-
5-[(methylamino)sulfonyl]-2-indolinone)
203996-37-6 (3-[(1,4-Benzopyranon-3-yl)methylidenyl]-5-
[(methylamino)sulfonyl]-2-indolinone)
203996-38-7 (3-(3-Cyanobenzylidenyl)-5-
[(methylamino)sulfonyl]-2-indolinone)
203996-39-8 (3-(4-Cyanobenzylidenyl)-5-
[(methylamino)sulfonyl]-2-indolinone)
203996-40-1 (3-(2,5-Dihydroxybenzylidenyl)-5-
[(methylamino)sulfonyl]-2-indolinone)
203996-41-2 (3-(2,3-Dimethoxybenzylidenyl)-5-
[(methylamino)sulfonyl]-2-indolinone)
203996-42-3 (3-[4-(Diethylamino)benzylidenyl]-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-43-4 (3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-
[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-44-5 (3-(3-Bromo-5-chloro-2-hydroxybenzylidenyl)-5-
[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-45-6 (3-[2-[(4-Chlorophenyl)thio]benzylidenyl]-5-
[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-46-7 (3-[(5-Chlorobenzodioxolan-6-yl)methylidenyl]-
5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-
indolinone)
203996-47-8 (3-[(1,4-Benzopyranon-3-yl)methylidenyl]-5-
[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-48-9 (3-(3-Cyanobenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-49-0 (3-(4-Cyanobenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-50-3 (3-(2,5-Dihydroxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-51-4 (3-(2,3-Dimethoxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203996-52-5 (3-[4-(Diethylamino)benzylidenyl]-5-
(morpholinosulfonyl)-2-indolinone)
203996-53-6 (3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-
(morpholinosulfonyl)-2-indolinone)
203996-54-7 (3-(3-Bromo-5-chloro-2-hydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
203996-55-8 (3-[2-[(4-Chlorophenyl)thio]benzylidenyl]-5-
(morpholinosulfonyl)-2-indolinone)
203996-56-9 (3-[(5-Chlorobenzodioxolan-6-yl)methylidenyl]-
5-(morpholinosulfonyl)-2-indolinone)
203996-57-0 (3-[(1,4-Benzopyranon-3-yl)methylidenyl]-5-
(morpholinosulfonyl)-2-indolinone)
203996-58-1 (3-(3-Cyanobenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
203996-59-2 (3-(4-Cyanobenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
203996-60-5 (3-(2,5-Dihydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
203996-61-6 (3-(2,3-Dimethoxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
203996-62-7 (3-[4-(Diethylamino)benzylidenyl]-5-(2-
chloroethyl)-2-indolinone)
203996-63-8 (3-[(2,4-Diethylpyrrol-5-yl)methylidenyl]-5-(2-
chloroethyl)-2-indolinone)
203996-64-9 (3-(3-Bromo-5-chloro-2-hydroxybenzylidenyl)-5-
(2-chloroethyl)-2-indolinone)

203996-65-0 (3-[2-[(4-Chlorophenyl)thio]benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203996-66-1 (3-[(5-Chlorobenzodioxolan-6-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203996-67-2 (3-[(1,4-Benzopyranon-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203996-68-3 (3-(3-Cyanobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203996-69-4 (3-(4-Cyanobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203996-70-7 (3-(2,5-Dihydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203996-71-8 (3-(2,3-Dimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203996-72-9 (3-(2,5-Dimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203996-73-0 (3-(2,6-Dimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203996-74-1 (3-(3,5-Dimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203996-75-2 (3-[4-(Dimethylamino)-2-methoxybenzylidenyl]-5,7-dibromo-2-indolinone)
203996-76-3 (3-[(Fluoren-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203996-77-4 (3-[2-Fluoro-3-(trifluoromethyl)benzylidenyl]-5,7-dibromo-2-indolinone)
203996-78-5 (3-[2-Fluoro-5-(trifluoromethyl)benzylidenyl]-5,7-dibromo-2-indolinone)
203996-79-6 (3-[2-Fluoro-6-(trifluoromethyl)benzylidenyl]-5,7-dibromo-2-indolinone)
203996-80-9 (3-[2-(Carboxymethoxy)benzylidenyl]-5,7-dibromo-2-indolinone)
203996-81-0 (3-[(4-Methoxybenzodioxolan-6-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203996-82-1 (3-(2,5-Dimethoxybenzylidenyl)-5-iodo-2-indolinone)
203996-83-2 (3-(2,6-Dimethoxybenzylidenyl)-5-iodo-2-indolinone)
203996-84-3 (3-(3,5-Dimethoxybenzylidenyl)-5-iodo-2-indolinone)
203996-85-4 (3-[4-(Dimethylamino)-2-methoxybenzylidenyl]-5-iodo-2-indolinone)
203996-86-5 (3-[(Fluoren-2-yl)methylidenyl]-5-iodo-2-indolinone)
203996-87-6 (3-[2-Fluoro-3-(trifluoromethyl)benzylidenyl]-5-iodo-2-indolinone)
203996-88-7 (3-[2-Fluoro-5-(trifluoromethyl)benzylidenyl]-5-iodo-2-indolinone)
203996-89-8 (3-[2-Fluoro-6-(trifluoromethyl)benzylidenyl]-5-iodo-2-indolinone)
203996-90-1 (3-[2-(Carboxymethoxy)benzylidenyl]-5-iodo-2-indolinone)
203996-91-2 (3-[(4-Methoxybenzodioxolan-6-yl)methylidenyl]-5-iodo-2-indolinone)
203996-92-3 (3-(2,5-Dimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203996-93-4 (3-(2,6-Dimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203996-94-5 (3-(3,5-Dimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203996-95-6 (3-[4-(Dimethylamino)-2-methoxybenzylidenyl]-5-bromo-4-methyl-2-indolinone)

203996-96-7 (3-[(Fluoren-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203996-97-8 (3-[2-Fluoro-3-(trifluoromethyl)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203996-98-9 (3-[2-Fluoro-5-(trifluoromethyl)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203996-99-0 (3-[2-Fluoro-6-(trifluoromethyl)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-00-6 (3-[2-(Carboxymethoxy)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-01-7 (3-[(4-Methoxybenzodioxolan-6-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-02-8 (3-(2,5-Dimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203997-03-9 (3-(2,6-Dimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203997-04-0 (3-(3,5-Dimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203997-05-1 (3-[4-(Dimethylamino)-2-methoxybenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-06-2 (3-[(Fluoren-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-07-3 (3-[2-Fluoro-3-(trifluoromethyl)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-08-4 (3-[2-Fluoro-5-(trifluoromethyl)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-09-5 (3-[2-Fluoro-6-(trifluoromethyl)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-10-8 (3-[2-(Carboxymethoxy)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-11-9 (3-[(4-Methoxybenzodioxolan-6-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-12-0 (3-(2,5-Dimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-13-1 (3-(2,6-Dimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-14-2 (3-(3,5-Dimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-15-3 (3-[4-(Dimethylamino)-2-methoxybenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-16-4 (3-[(Fluoren-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-17-5 (3-[2-Fluoro-3-(trifluoromethyl)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-18-6 (3-[2-Fluoro-5-(trifluoromethyl)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-19-7 (3-[2-Fluoro-6-(trifluoromethyl)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-20-0 (3-[2-(Carboxymethoxy)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-21-1 (3-[(4-Methoxybenzodioxolan-6-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-22-2 (3-(2,5-Dimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203997-23-3 (3-(2,6-Dimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203997-24-4 (3-(3,5-Dimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)

203997-25-5 (3-[4-(Dimethylamino)-2-methoxybenzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-26-6 (3-[(Fluoren-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-27-7 (3-[2-Fluoro-3-(trifluoromethyl)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-28-8 (3-[2-Fluoro-5-(trifluoromethyl)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-29-9 (3-[2-Fluoro-6-(trifluoromethyl)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-30-2 (3-[2-(Carboxymethoxy)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-31-3 (3-[(4-Methoxybenzodioxolan-6-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-32-4 (3-(2,5-Dimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203997-33-5 (3-(2,6-Dimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203997-34-6 (3-(3,5-Dimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203997-35-7 (3-[4-(Dimethylamino)-2-methoxybenzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203997-36-8 (3-[(Fluoren-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203997-37-9 (3-[2-Fluoro-3-(trifluoromethyl)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203997-38-0 (3-[2-Fluoro-5-(trifluoromethyl)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203997-39-1 (3-[2-Fluoro-6-(trifluoromethyl)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203997-40-4 (3-[2-(Carboxymethoxy)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203997-41-5 (3-[(4-Methoxybenzodioxolan-6-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203997-42-6 (3-[(2-Methoxynaphth-1-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203997-43-7 (3-[(1-Methoxynaphth-4-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203997-44-8 (3-[4-(Methylthio)benzylidenyl]-5,7-dibromo-2-indolinone)
203997-45-9 (3-[(3-Methylthien-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203997-46-0 (3-(3-Phenoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203997-47-1 (3-[(Pyrid-2-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203997-48-2 (3-[(Pyrid-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203997-49-3 (3-[(Pyrid-4-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203997-50-6 (3-[4-(Pyrrolidin-1-yl)benzylidenyl]-5,7-dibromo-2-indolinone)
203997-51-7 (3-[(Cyclohexen-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203997-52-8 (3-[(2-Methoxynaphth-1-yl)methylidenyl]-5-iodo-2-indolinone)
203997-53-9 (3-[(1-Methoxynaphth-4-yl)methylidenyl]-5-iodo-2-indolinone)
203997-54-0 (3-[4-(Methylthio)benzylidenyl]-5-iodo-2-indolinone)
203997-55-1 (3-[(3-Methylthien-2-yl)methylidenyl]-5-iodo-2-indolinone)

203997-56-2 (3-(3-Phenoxybenzylidenyl)-5-iodo-2-indolinone)
203997-57-3 (3-[(Pyrid-2-yl)methylidenyl]-5-iodo-2-indolinone)
203997-58-4 (3-[(Pyrid-3-yl)methylidenyl]-5-iodo-2-indolinone)
203997-59-5 (3-[(Pyrid-4-yl)methylidenyl]-5-iodo-2-indolinone)
203997-60-8 (3-[4-(Pyrrolidin-1-yl)benzylidenyl]-5-iodo-2-indolinone)
203997-61-9 (3-[(Cyclohexen-3-yl)methylidenyl]-5-iodo-2-indolinone)
203997-62-0 (3-[(2-Methoxynaphth-1-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-63-1 (3-[(1-Methoxynaphth-4-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-64-2 (3-[4-(Methylthio)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-65-3 (3-[(3-Methylthien-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-66-4 (3-(3-Phenoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203997-67-5 (3-[(Pyrid-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-68-6 (3-[(Pyrid-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-69-7 (3-[(Pyrid-4-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-70-0 (3-[4-(Pyrrolidin-1-yl)benzylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-71-1 (3-[(Cyclohexen-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203997-72-2 (3-[(2-Methoxynaphth-1-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-73-3 (3-[(1-Methoxynaphth-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-74-4 (3-[4-(Methylthio)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-75-5 (3-[(3-Methylthien-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-76-6 (3-(3-Phenoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203997-77-7 (3-[(Pyrid-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-78-8 (3-[(Pyrid-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-79-9 (3-[(Pyrid-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-81-3 (3-[4-(Pyrrolidin-1-yl)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-83-5 (3-[(Cyclohexen-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203997-85-7 (3-[(2-Methoxynaphth-1-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-87-9 (3-[(1-Methoxynaphth-4-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-89-1 (3-[4-(Methylthio)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-90-4 (3-[(3-Methylthien-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-91-5 (3-(3-Phenoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)

203997-92-6 (3-[(Pyrid-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-93-7 (3-[(Pyrid-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-94-8 (3-[(Pyrid-4-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-95-9 (3-[4-(Pyrrolidin-1-yl)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-96-0 (3-[(Cyclohexen-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203997-97-1 (3-[(2-Methoxynaphth-1-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-98-2 (3-[(1-Methoxynaphth-4-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203997-99-3 (3-[4-(Methylthio)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-00-9 (3-[(3-Methylthien-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-01-0 (3-(3-Phenoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203998-02-1 (3-[(Pyrid-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-03-2 (3-[(Pyrid-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-04-3 (3-[(Pyrid-4-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-05-4 (3-[4-(Pyrrolidin-1-yl)benzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-06-5 (3-[(Cyclohexen-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-07-6 (3-[(2-Methoxynaphth-1-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-08-7 (3-[(1-Methoxynaphth-4-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-09-8 (3-[4-(Methylthio)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-10-1 (3-[(3-Methylthien-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-11-2 (3-(3-Phenoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203998-12-3 (3-[(Pyrid-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-13-4 (3-[(Pyrid-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-14-5 (3-[(Pyrid-4-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-15-6 (3-[4-(Pyrrolidin-1-yl)benzylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-16-7 (3-[(Cyclohexen-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-17-8 (3-(2,3,4-Trimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203998-18-9 (3-(2,4,5-Trimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203998-19-0 (3-(3,4,5-Trimethoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203998-20-3 (3-[(1-Acetylindol-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-21-4 (3-[(6-Chloro-1,4-benzopyranon-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-22-5 (3-[[2-(2-Chlorophenyl)furan-5-yl]methylidenyl]-5,7-dibromo-2-indolinone)

203998-23-6 (3-[(2-Chloroquinolin-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-24-7 (3-[(6,8-Dibromo-1,4-benzopyranon-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-25-8 (3-[(2,5-Dimethoxytetrahydrofuran-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-26-9 (3-[(2,3-Dimethylfuran-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-27-0 (3-(2,3,4-Trimethoxybenzylidenyl)-5-iodo-2-indolinone)
203998-28-1 (3-(2,4,5-Trimethoxybenzylidenyl)-5-iodo-2-indolinone)
203998-29-2 (3-(3,4,5-Trimethoxybenzylidenyl)-5-iodo-2-indolinone)
203998-30-5 (3-[(1-Acetylindol-3-yl)methylidenyl]-5-iodo-2-indolinone)
203998-31-6 (3-[(6-Chloro-1,4-benzopyranon-3-yl)methylidenyl]-5-iodo-2-indolinone)
203998-32-7 (3-[[2-(2-Chlorophenyl)furan-5-yl]methylidenyl]-5-iodo-2-indolinone)
203998-33-8 (3-[(2-Chloroquinolin-3-yl)methylidenyl]-5-iodo-2-indolinone)
203998-34-9 (3-[(6,8-Dibromo-1,4-benzopyranon-3-yl)methylidenyl]-5-iodo-2-indolinone)
203998-35-0 (3-[(2,5-Dimethoxytetrahydrofuran-3-yl)methylidenyl]-5-iodo-2-indolinone)
203998-36-1 (3-[(2,3-Dimethylfuran-5-yl)methylidenyl]-5-iodo-2-indolinone)
203998-37-2 (3-(2,3,4-Trimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203998-38-3 (3-(2,4,5-Trimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203998-39-4 (3-(3,4,5-Trimethoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
203998-40-7 (3-[(1-Acetylindol-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203998-41-8 (3-[(6-Chloro-1,4-benzopyranon-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203998-42-9 (3-[[2-(2-Chlorophenyl)furan-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203998-43-0 (3-[(2-Chloroquinolin-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203998-44-1 (3-[(6,8-Dibromo-1,4-benzopyranon-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203998-45-2 (3-[(2,5-Dimethoxytetrahydrofuran-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203998-46-3 (3-[(2,3-Dimethylfuran-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203998-47-4 (3-(2,3,4-Trimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203998-48-5 (3-(2,4,5-Trimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203998-49-6 (3-(3,4,5-Trimethoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
203998-50-9 (3-[(1-Acetylindol-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203998-51-0 (3-[(6-Chloro-1,4-benzopyranon-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203998-52-1 (3-[[2-(2-Chlorophenyl)furan-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203998-53-2 (3-[(2-Chloroquinolin-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)

REGISTRY NUMBER:

203998-54-3 (3-[(6,8-Dibromo-1,4-benzopyranon-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203998-55-4 (3-[(2,5-Dimethoxytetrahydrofuran-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203998-56-5 (3-[(2,3-Dimethylfuran-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203998-57-6 (3-(2,3,4-Trimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-58-7 (3-(2,4,5-Trimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-59-8 (3-(3,4,5-Trimethoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-60-1 (3-[(1-Acetylindol-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-61-2 (3-[(6-Chloro-1,4-benzopyranon-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-62-3 (3-[[2-(2-Chlorophenyl)furan-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-63-4 (3-[(2-Chloroquinolin-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-64-5 (3-[(6,8-Dibromo-1,4-benzopyranon-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-65-6 (3-[(2,5-Dimethoxytetrahydrofuran-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-66-7 (3-[(2,3-Dimethylfuran-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203998-67-8 (3-(2,3,4-Trimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203998-68-9 (3-(2,4,5-Trimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203998-69-0 (3-(3,4,5-Trimethoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
203998-70-3 (3-[(1-Acetylindol-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-71-4 (3-[(6-Chloro-1,4-benzopyranon-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-72-5 (3-[[2-(2-Chlorophenyl)furan-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-73-6 (3-[(2-Chloroquinolin-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-74-7 (3-[(6,8-Dibromo-1,4-benzopyranon-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-75-8 (3-[(2,5-Dimethoxytetrahydrofuran-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-76-9 (3-[(2,3-Dimethylfuran-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203998-77-0 (3-(2,3,4-Trimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203998-78-1 (3-(2,4,5-Trimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203998-79-2 (3-(3,4,5-Trimethoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
203998-80-5 (3-[(1-Acetylindol-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-81-6 (3-[(6-Chloro-1,4-benzopyranon-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-82-7 (3-[[2-(2-Chlorophenyl)furan-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)

203998-83-8 (3-[(2-Chloroquinolin-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-84-9 (3-[(6,8-Dibromo-1,4-benzopyranon-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-85-0 (3-[(2,5-Dimethoxytetrahydrofuran-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-86-1 (3-[(2,3-Dimethylfuran-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203998-87-2 (3-[(9-Ethylcarbazol-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-88-3 (3-[(6,7-Dimethyl-1,4-benzopyron-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-89-4 (3-[[4-(Propen-2-yl)cyclohexen-1-yl]methylidenyl]-5,7-dibromo-2-indolinone)
203998-90-7 (3-[(6-Isopropyl-1,4-benzopyron-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-91-8 (3-[(6-Methyl-1,4-benzopyron-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-92-9 (3-[(6-Nitro-1,4-benzopyron-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-93-0 (3-[(Pyrimid-2,4-dion-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-94-1 (3-[(5-Methoxyindol-3-yl)methylidenyl]-5,7-dibromo-2-indolinone)
203998-96-3 (3-[[2-(2-Nitrophenyl)furan-5-yl]methylidene]-5,7-dibromo-2-indolinone)
203998-97-4 (3-[(9-Ethylcarbazol-3-yl)methylidenyl]-5-iodo-2-indolinone)
203999-01-3 (3-[(6,7-Dimethyl-1,4-benzopyron-3-yl)methylidenyl]-5-iodo-2-indolinone)
203999-02-4 (3-[[4-(Propen-2-yl)cyclohexen-1-yl]methylidenyl]-5-iodo-2-indolinone)
203999-03-5 (3-[(6-Isopropyl-1,4-benzopyron-3-yl)methylidenyl]-5-iodo-2-indolinone)
203999-04-6 (3-[(6-Methyl-1,4-benzopyron-3-yl)methylidenyl]-5-iodo-2-indolinone)
203999-05-7 (3-[(6-Nitro-1,4-benzopyron-3-yl)methylidenyl]-5-iodo-2-indolinone)
203999-06-8 (3-[(Pyrimid-2,4-dion-5-yl)methylidenyl]-5-iodo-2-indolinone)
203999-07-9 (3-[(5-Methoxyindol-3-yl)methylidenyl]-5-iodo-2-indolinone)
203999-09-1 (3-[[2-(2-Nitrophenyl)furan-5-yl]methylidene]-5-iodo-2-indolinone)
203999-10-4 (3-[(9-Ethylcarbazol-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203999-11-5 (3-[(6,7-Dimethyl-1,4-benzopyron-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203999-12-6 (3-[[4-(Propen-2-yl)cyclohexen-1-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone)
203999-13-7 (3-[(6-Isopropyl-1,4-benzopyron-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203999-14-8 (3-[(6-Methyl-1,4-benzopyron-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203999-15-9 (3-[(6-Nitro-1,4-benzopyron-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203999-17-1 (3-[(5-Methoxyindol-3-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
203999-19-3 (3-[[2-(2-Nitrophenyl)furan-5-yl]methylidene]-5-bromo-4-methyl-2-indolinone)
203999-20-6 (3-[(9-Ethylcarbazol-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)

203999-21-7 (3-[(6,7-Dimethyl-1,4-benzopyron-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203999-22-8 (3-[[4-(Propen-2-yl)cyclohexen-1-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203999-23-9 (3-[(6-Isopropyl-1,4-benzopyron-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203999-24-0 (3-[(6-Methyl-1,4-benzopyron-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203999-25-1 (3-[(6-Nitro-1,4-benzopyron-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203999-27-3 (3-[(5-Methoxyindol-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
203999-29-5 (3-[[2-(2-Nitrophenyl)furan-5-yl]methylidene]-5-[(methylamino)sulfonyl]-2-indolinone)
203999-30-8 (3-[(9-Ethylcarbazol-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203999-31-9 (3-[(6,7-Dimethyl-1,4-benzopyron-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203999-32-0 (3-[[4-(Propen-2-yl)cyclohexen-1-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203999-33-1 (3-[(6-Isopropyl-1,4-benzopyron-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203999-36-4 (3-[(6-Methyl-1,4-benzopyron-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203999-38-6 (3-[(6-Nitro-1,4-benzopyron-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203999-42-2 (3-[(5-Methoxyindol-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203999-46-6 (3-[[2-(2-Nitrophenyl)furan-5-yl]methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
203999-47-7 (3-[(9-Ethylcarbazol-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203999-48-8 (3-[(6,7-Dimethyl-1,4-benzopyron-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203999-49-9 (3-[[4-(Propen-2-yl)cyclohexen-1-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203999-50-2 (3-[(6-Isopropyl-1,4-benzopyron-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203999-51-3 (3-[(6-Methyl-1,4-benzopyron-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203999-52-4 (3-[(6-Nitro-1,4-benzopyron-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203999-54-6 (3-[(5-Methoxyindol-3-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
203999-56-8 (3-[[2-(2-Nitrophenyl)furan-5-yl]methylidene]-5-(morpholinosulfonyl)-2-indolinone)
203999-57-9 (3-[(9-Ethylcarbazol-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203999-58-0 (3-[(6,7-Dimethyl-1,4-benzopyron-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203999-59-1 (3-[[4-(Propen-2-yl)cyclohexen-1-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203999-61-5 (3-[(6-Isopropyl-1,4-benzopyron-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203999-63-7 (3-[(6-Methyl-1,4-benzopyron-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)

203999-65-9 (3-[(6-Nitro-1,4-benzopyron-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203999-69-3 (3-[(5-Methoxyindol-3-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
203999-73-9 (3-[[2-(2-Nitrophenyl)furan-5-yl]methylidene]-5-(2-chloroethyl)-2-indolinone)
203999-75-1 (3-[2-(Thien-2-yl)-2-(trifluoromethyl)ethylidenyl]-5,7-dibromo-2-indolinone)
203999-77-3 (3-(3,5-Diisopropyl-4-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203999-79-5 (3-(3,5-Diisopropyl-4-phenoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203999-81-9 (3-(3-tert-Butyl-4-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203999-83-1 (3-[4-(Benzyloxy)-3-tert-butylbenzylidenyl]-5,7-dibromo-2-indolinone)
203999-85-3 (3-(3-Bromo-5-tert-butyl-4-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203999-87-5 (3-[4-(Benzyloxy)-3-bromo-5-tert-butylbenzylidenyl]-5,7-dibromo-2-indolinone)
203999-89-7 (3-(3-tert-Butyl-5-chloro-4-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203999-91-1 (3-[4-(Benzyloxy)-5-tert-butyl-3-chlorobenzylidenyl]-5,7-dibromo-2-indolinone)
203999-93-3 (3-(3-tert-Butyl-5-iodo-4-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
203999-95-5 (3-[2-(Thien-2-yl)-2-(trifluoromethyl)ethylidenyl]-5-iodo-2-indolinone)
203999-97-7 (3-(3,5-Diisopropyl-4-methoxybenzylidenyl)-5-iodo-2-indolinone)
203999-99-9 (3-(3,5-Diisopropyl-4-phenoxybenzylidenyl)-5-iodo-2-indolinone)
204000-01-1 (3-(3-tert-Butyl-4-methoxybenzylidenyl)-5-iodo-2-indolinone)
204000-03-3 (3-[4-(Benzyloxy)-3-tert-butylbenzylidenyl]-5-iodo-2-indolinone)
204000-05-5 (3-(3-Bromo-5-tert-butyl-4-methoxybenzylidenyl)-5-iodo-2-indolinone)
204000-07-7 (3-[4-(Benzyloxy)-3-bromo-5-tert-butylbenzylidenyl]-5-iodo-2-indolinone)
204000-09-9 (3-(3-tert-Butyl-5-chloro-4-methoxybenzylidenyl)-5-iodo-2-indolinone)
204000-13-5 (3-[4-(Benzyloxy)-5-tert-butyl-3-chlorobenzylidenyl]-5-iodo-2-indolinone)
204000-17-9 (3-(3-tert-Butyl-5-iodo-4-methoxybenzylidenyl)-5-iodo-2-indolinone)
204000-19-1 (3-[2-(Thien-2-yl)-2-(trifluoromethyl)ethylidenyl]-5-bromo-4-methyl-2-indolinone)
204000-21-5 (3-(3,5-Diisopropyl-4-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204000-23-7 (3-(3,5-Diisopropyl-4-phenoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204000-25-9 (3-(3-tert-Butyl-4-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204000-27-1 (3-[4-(Benzyloxy)-3-tert-butylbenzylidenyl]-5-bromo-4-methyl-2-indolinone)
204000-29-3 (3-(3-Bromo-5-tert-butyl-4-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204000-31-7 (3-[4-(Benzyloxy)-3-bromo-5-tert-butylbenzylidenyl]-5-bromo-4-methyl-2-indolinone)
204000-33-9 (3-(3-tert-Butyl-5-chloro-4-

methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204000-34-0 (3-[4-(Benzyloxy)-5-tert-butyl-3-chlorobenzylidenyl]-5-bromo-4-methyl-2-indolinone)
204000-36-2 (3-(3-tert-Butyl-5-iodo-4-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204000-37-3 (3-[2-(Thien-2-yl)-2-(trifluoromethyl)ethylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
204000-38-4 (3-(3,5-Diisopropyl-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204000-39-5 (3-(3,5-Diisopropyl-4-phenoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204000-40-8 (3-(3-tert-Butyl-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204000-41-9 (3-[4-(Benzyloxy)-3-tert-butylbenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
204000-42-0 (3-(3-Bromo-5-tert-butyl-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204000-43-1 (3-[4-(Benzyloxy)-3-bromo-5-tert-butylbenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
204000-44-2 (3-(3-tert-Butyl-5-chloro-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204000-45-3 (3-[4-(Benzyloxy)-5-tert-butyl-3-chlorobenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
204000-46-4 (3-(3-tert-Butyl-5-iodo-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204000-47-5 (3-[2-(Thien-2-yl)-2-(trifluoromethyl)ethylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-48-6 (3-(3,5-Diisopropyl-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-49-7 (3-(3,5-Diisopropyl-4-phenoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-50-0 (3-(3-tert-Butyl-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-51-1 (3-[4-(Benzyloxy)-3-tert-butylbenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-52-2 (3-(3-Bromo-5-tert-butyl-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-53-3 (3-[4-(Benzyloxy)-3-bromo-5-tert-butylbenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-54-4 (3-(3-tert-Butyl-5-chloro-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-55-5 (3-[4-(Benzyloxy)-5-tert-butyl-3-chlorobenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-56-6 (3-(3-tert-Butyl-5-iodo-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204000-57-7 (3-[2-(Thien-2-yl)-2-(trifluoromethyl)ethylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
204000-58-8 (3-(3,5-Diisopropyl-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
204000-59-9 (3-(3,5-Diisopropyl-4-phenoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)

204000-60-2 (3-(3-tert-Butyl-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
204000-61-3 (3-[4-(Benzyloxy)-3-tert-butylbenzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
204000-62-4 (3-(3-Bromo-5-tert-butyl-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
204000-63-5 (3-[4-(Benzyloxy)-3-bromo-5-tert-butylbenzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
204000-64-6 (3-(3-tert-Butyl-5-chloro-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
204000-65-7 (3-[4-(Benzyloxy)-5-tert-butyl-3-chlorobenzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
204000-66-8 (3-(3-tert-Butyl-5-iodo-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
204000-67-9 (3-[2-(Thien-2-yl)-2-(trifluoromethyl)ethylidenyl]-5-(2-chloroethyl)-2-indolinone)
204000-68-0 (3-(3,5-Diisopropyl-4-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204000-69-1 (3-(3,5-Diisopropyl-4-phenoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204000-70-4 (3-(3-tert-Butyl-4-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204000-71-5 (3-[4-(Benzyloxy)-3-tert-butylbenzylidenyl]-5-(2-chloroethyl)-2-indolinone)
204000-72-6 (3-(3-Bromo-5-tert-butyl-4-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204000-73-7 (3-[4-(Benzyloxy)-3-bromo-5-tert-butylbenzylidenyl]-5-(2-chloroethyl)-2-indolinone)
204000-74-8 (3-(3-tert-Butyl-5-chloro-4-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204000-75-9 (3-[4-(Benzyloxy)-5-tert-butyl-3-chlorobenzylidenyl]-5-(2-chloroethyl)-2-indolinone)
204000-76-0 (3-(3-tert-Butyl-5-iodo-4-methoxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204000-77-1 (3-[4-(Benzyloxy)-3-tert-butyl-5-iodobenzylidenyl]-5,7-dibromo-2-indolinone)
204000-78-2 (3-(3-tert-Butyl-4-methoxy-5-nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
204000-79-3 (3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
204000-80-6 (3-[4-(Benzyloxy)-3,5-di-tert-butylbenzylidenyl]-5,7-dibromo-2-indolinone)
204000-81-7 (3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
204000-82-8 (3-[4-(Benzyloxy)-3,5-dimethylbenzylidenyl]-5,7-dibromo-2-indolinone)
204000-83-9 (3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5,7-dibromo-2-indolinone)
204000-84-0 (3-(5-Bromo-2-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
204000-85-1 (3-(2-Hydroxy-5-nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
204000-86-2 (3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
204000-87-3 (3-[4-(Benzyloxy)-3-tert-butyl-5-iodobenzylidenyl]-5-iodo-2-indolinone)
204000-88-4 (3-(3-tert-Butyl-4-methoxy-5-nitrobenzylidenyl)-5-iodo-2-indolinone)
204000-89-5 (3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-iodo-2-indolinone)
204000-90-8 (3-[4-(Benzyloxy)-3,5-di-tert-

butylbenzylidenyl]-5-iodo-2-indolinone)
204000-91-9 (3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-iodo-2-indolinone)
204000-92-0 (3-[4-(Benzyloxy)-3,5-dimethylbenzylidenyl]-5-iodo-2-indolinone)
204000-93-1 (3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-iodo-2-indolinone)
204000-94-2 (3-(5-Bromo-2-hydroxybenzylidenyl)-5-iodo-2-indolinone)
204000-95-3 (3-(2-Hydroxy-5-nitrobenzylidenyl)-5-iodo-2-indolinone)
204000-96-4 (3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-iodo-2-indolinone)
204000-97-5 (3-[4-(Benzyloxy)-3-tert-butyl-5-iodobenzylidenyl]-5-bromo-4-methyl-2-indolinone)
204000-98-6 (3-(3-tert-Butyl-4-methoxy-5-nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204000-99-7 (3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-00-3 (3-[4-(Benzyloxy)-3,5-di-tert-butylbenzylidenyl]-5-bromo-4-methyl-2-indolinone)
204001-01-4 (3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-02-5 (3-[4-(Benzyloxy)-3,5-dimethylbenzylidenyl]-5-bromo-4-methyl-2-indolinone)
204001-03-6 (3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-04-7 (3-(5-Bromo-2-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-05-8 (3-(2-Hydroxy-5-nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-06-9 (3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-07-0 (3-[4-(Benzyloxy)-3-tert-butyl-5-iodobenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
204001-08-1 (3-(3-tert-Butyl-4-methoxy-5-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-09-2 (3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-10-5 (3-[4-(Benzyloxy)-3,5-di-tert-butylbenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
204001-11-6 (3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-12-7 (3-[4-(Benzyloxy)-3,5-dimethylbenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)
204001-13-8 (3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-14-9 (3-(5-Bromo-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-15-0 (3-(2-Hydroxy-5-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-16-1 (3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-17-2 (3-[4-(Benzyloxy)-3-tert-butyl-5-iodobenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-18-3 (3-(3-tert-Butyl-4-methoxy-5-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-19-4 (3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-21-8 (3-[4-(Benzyloxy)-3,5-di-tert-

butylbenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]su
lfonyl]-2-indolinone)
204001-22-9 (3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-23-0 (3-[4-(Benzyloxy)-3,5-dimethylbenzylidenyl]-5-
[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-24-1 (3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-
[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-25-2 (3-(5-Bromo-2-hydroxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-26-3 (3-(2-Hydroxy-5-nitrobenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-27-4 (3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-
[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-28-5 (3-[4-(Benzyloxy)-3-tert-butyl-5-
iodobenzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
204001-29-6 (3-(3-tert-Butyl-4-methoxy-5-
nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone)
204001-30-9 (3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204001-31-0 (3-[4-(Benzyloxy)-3,5-di-tert-
butylbenzylidenyl]-5-(morpholinosulfonyl)-2-indolinone)
204001-32-1 (3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204001-33-2 (3-[4-(Benzyloxy)-3,5-dimethylbenzylidenyl]-5-
(morpholinosulfonyl)-2-indolinone)
204001-34-3 (3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204001-35-4 (3-(5-Bromo-2-hydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204001-36-5 (3-(2-Hydroxy-5-nitrobenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204001-37-6 (3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204001-38-7 (3-[4-(Benzyloxy)-3-tert-butyl-5-
iodobenzylidenyl]-5-(2-chloroethyl)-2-indolinone)
204001-39-8 (3-(3-tert-Butyl-4-methoxy-5-
nitrobenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204001-40-1 (3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-
(2-chloroethyl)-2-indolinone)
204001-41-2 (3-[4-(Benzyloxy)-3,5-di-tert-
butylbenzylidenyl]-5-(2-chloroethyl)-2-indolinone)
204001-42-3 (3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-(2-
chloroethyl)-2-indolinone)
204001-43-4 (3-[4-(Benzyloxy)-3,5-dimethylbenzylidenyl]-5-
(2-chloroethyl)-2-indolinone)
204001-44-5 (3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-
(2-chloroethyl)-2-indolinone)
204001-45-6 (3-(5-Bromo-2-hydroxybenzylidenyl)-5-(2-
chloroethyl)-2-indolinone)
204001-46-7 (3-(2-Hydroxy-5-nitrobenzylidenyl)-5-(2-
chloroethyl)-2-indolinone)
204001-47-8 (3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-
(2-chloroethyl)-2-indolinone)
204001-48-9 (3-(3-Ethoxy-2-hydroxybenzylidenyl)-5,7-
dibromo-2-indolinone)
204001-49-0 (3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5,7-
dibromo-2-indolinone)
204001-50-3 (3-(5-Chloro-2-hydroxybenzylidenyl)-5,7-
dibromo-2-indolinone)
204001-51-4 (3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-
5,7-dibromo-2-indolinone)

204001-52-5 (3-(4-Nitrobenzylidenyl)-5,7-dibromo-2-indolinone)
204001-53-6 (3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
204001-54-7 (3-(3-Fluoro-2-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
204001-55-8 (3-(3-Bromo-4-hydroxybenzylidenyl)-5,7-dibromo-2-indolinone)
204001-56-9 (3-(4-tert-Butylbenzylidenyl)-5,7-dibromo-2-indolinone)
204001-57-0 (3-[(2-Bromothien-5-yl)methylidenyl]-5,7-dibromo-2-indolinone)
204001-58-1 (3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-iodo-2-indolinone)
204001-59-2 (3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-iodo-2-indolinone)
204001-60-5 (3-(5-Chloro-2-hydroxybenzylidenyl)-5-iodo-2-indolinone)
204001-61-6 (3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-5-iodo-2-indolinone)
204001-62-7 (3-(4-Nitrobenzylidenyl)-5-iodo-2-indolinone)
204001-63-8 (3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-iodo-2-indolinone)
204001-64-9 (3-(3-Fluoro-2-hydroxybenzylidenyl)-5-iodo-2-indolinone)
204001-65-0 (3-(3-Bromo-4-hydroxybenzylidenyl)-5-iodo-2-indolinone)
204001-66-1 (3-(4-tert-Butylbenzylidenyl)-5-iodo-2-indolinone)
204001-67-2 (3-[(2-Bromothien-5-yl)methylidenyl]-5-iodo-2-indolinone)
204001-68-3 (3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-69-4 (3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-70-7 (3-(5-Chloro-2-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-71-8 (3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-5-bromo-4-methyl-2-indolinone)
204001-72-9 (3-(4-Nitrobenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-73-0 (3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-74-1 (3-(3-Fluoro-2-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-75-2 (3-(3-Bromo-4-hydroxybenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-76-3 (3-(4-tert-Butylbenzylidenyl)-5-bromo-4-methyl-2-indolinone)
204001-77-4 (3-[(2-Bromothien-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone)
204001-78-5 (3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-79-6 (3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-80-9 (3-(5-Chloro-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-81-0 (3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone)

REGISTRY NUMBER:

204001-82-1 (3-(4-Nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone)
204001-83-2 (3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-

[(methylamino)sulfonyl]-2-indolinone)
204001-84-3 (3-(3-Fluoro-2-hydroxybenzylidenyl)-5-
[(methylamino)sulfonyl]-2-indolinone)
204001-85-4 (3-(3-Bromo-4-hydroxybenzylidenyl)-5-
[(methylamino)sulfonyl]-2-indolinone)
204001-86-5 (3-(4-tert-Butylbenzylidenyl)-5-
[(methylamino)sulfonyl]-2-indolinone)
204001-87-6 (3-[(2-Bromothien-5-yl)methylidenyl]-5-
[(methylamino)sulfonyl]-2-indolinone)
204001-88-7 (3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-89-8 (3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-90-1 (3-(5-Chloro-2-hydroxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-91-2 (3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-5-
[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-92-3 (3-(4-Nitrobenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-93-4 (3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-94-5 (3-(3-Fluoro-2-hydroxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-95-6 (3-(3-Bromo-4-hydroxybenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-96-7 (3-(4-tert-Butylbenzylidenyl)-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-97-8 (3-[(2-Bromothien-5-yl)methylidenyl]-5-[[[4-
(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone)
204001-98-9 (3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204001-99-0 (3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204002-00-6 (3-(5-Chloro-2-hydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204002-01-7 (3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-5-
(morpholinosulfonyl)-2-indolinone)
204002-02-8 (3-(4-Nitrobenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204002-03-9 (3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204002-04-0 (3-(3-Fluoro-2-hydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204002-05-1 (3-(3-Bromo-4-hydroxybenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204002-06-2 (3-(4-tert-Butylbenzylidenyl)-5-
(morpholinosulfonyl)-2-indolinone)
204002-07-3 (3-[(2-Bromothien-5-yl)methylidenyl]-5-
(morpholinosulfonyl)-2-indolinone)
204002-08-4 (3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-(2-
chloroethyl)-2-indolinone)
204002-09-5 (3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-(2-
chloroethyl)-2-indolinone)
204002-10-8 (3-(5-Chloro-2-hydroxybenzylidenyl)-5-(2-
chloroethyl)-2-indolinone)
204002-11-9 (3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-5-
(2-chloroethyl)-2-indolinone)
204002-12-0 (3-(4-Nitrobenzylidenyl)-5-(2-chloroethyl)-2-
indolinone)
204002-13-1 (3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-(2-
chloroethyl)-2-indolinone)
204002-14-2 (3-(3-Fluoro-2-hydroxybenzylidenyl)-5-(2-

chloroethyl)-2-indolinone)
204002-15-3 (3-(3-Bromo-4-hydroxybenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204002-16-4 (3-(4-tert-Butylbenzylidenyl)-5-(2-chloroethyl)-2-indolinone)
204002-17-5 (3-[(2-Bromothien-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone)
204007-13-6 (3-(4-Hydroxy-3-methylbenzylidenyl)-5-bromo-4-methyl-2-indolinone)
59-48-3 (2-Oxindole)
59-48-3Q (Oxindole, derivs.)
83-41-0 (3-Nitro-o-xylene)
95-92-1 (Diethyl oxalate)
443-69-6 (5-Fluoroisatin)
625-82-1 (2,4-Dimethylpyrrole)
7424-54-6 (3,5-Heptanedione)
13433-00-6 (Diethyl aminomalonate hydrochloride)
193354-13-1 (5-Iodo-2-oxindole)

REGISTRY NUMBER: 22813-84-9; 91822-51-4; 168464-14-0; 186610-89-9; 186611-40-5; 186611-53-0; 203995-44-2; 203995-45-3; 203995-53-3; 203995-54-4; 203995-62-4; 203995-63-5; 203995-71-5; 203995-72-6; 203995-80-6; 203995-81-7; 203995-89-5; 203995-90-8; 203995-98-6; 203995-99-7; 203998-95-2; 203999-08-0; 203999-16-0; 203999-18-2; 203999-26-2; 203999-28-4; 203999-40-0; 203999-44-4; 203999-53-5; 203999-55-7; 203999-67-1; 203999-71-7; 204003-31-6; 204003-32-7; 204003-42-9; 204003-84-9; 204003-85-0; 204003-88-3; 204003-89-4; 204003-90-7; 204003-91-8; 204003-96-3; 204003-97-4; 204004-10-4; 204004-11-5; 204004-29-5; 204004-86-4; 204004-92-2; 204004-94-4; 204005-03-8; 204005-21-0; 204005-38-9; 204005-39-0; 204005-46-9; 204005-54-9; 204005-56-1; 204005-58-3; 204005-59-4; 204005-60-7; 204005-66-3; 204005-67-4; 204005-71-0; 204005-75-4; 204005-76-5; 204005-90-3; 204006-01-9; 204006-02-0; 204006-03-1; 204006-04-2; 204006-05-3; 204006-06-4; 204006-19-9; 204006-26-8; 204006-35-9; 204006-83-7; 204006-93-9; 204006-96-2; 204006-98-4

L16 ANSWER 17 OF 19 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-221284 [21] WPIDS
DOC. NO. CPI: C2003-056064
TITLE: New 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-**indolinone** derivatives are **protein kinase inhibitors** used for treating e.g. cancer, diabetic retinopathy, atherosclerosis and immunological disease.
DERWENT CLASS: B02
INVENTOR(S): **CUI, J**; LIANG, C; RAMPHAL, J; SUN, C L; **TANG, P C**; **WEI, C C**; RAMPHAL, Y; SUN, L
PATENT ASSIGNEE(S): (SUGE-N) SUGEN INC; (CUIJ-I) CUI J
COUNTRY COUNT: 100
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2002096361	A2	20021205	(200321)*	EN	240	A61K000-00

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT

RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

US 2003125370	A1 20030703 (200345)		A61K031-405
US 6599902	B2 20030729 (200354)		A61K031-5377
AU 2002303892	A1 20021209 (200452)		A61K000-00

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002096361	A2	WO 2002-US16841	20020530
US 2003125370	A1 Provisional	US 2001-294544P	20010530
	Provisional	US 2001-328408P	20011010
		US 2002-157007	20020530
US 6599902	B2 Provisional	US 2001-294544P	20010530
	Provisional	US 2001-328408P	20011010
		US 2002-157007	20020530
AU 2002303892	A1	AU 2002-303892	20020530

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002303892	A1 Based on	WO 2002096361

PRIORITY APPLN. INFO: US 2001-328408P 20011010; US 2001-294544P 20010530; US 2002-157007 20020530

INT. PATENT CLASSIF.:
MAIN: A61K000-00; A61K031-405; A61K031-5377
SECONDARY: A61P035-00; C07D403-02; C07D403-06; C07D403-14; C07D413-04

BASIC ABSTRACT:

WO 200296361 A UPAB: 20030328

NOVELTY - 5-Aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives (I) are new.

DETAILED DESCRIPTION - 5-Aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives of formula (I) and their salts are new.

n = 0-2;

m = 1-3;

R1, R2 = H or alkyl;

R3-R5 = halo, haloalkyl, OH, alkoxy, haloalkoxy, CN, NO2, aryloxy, heteroaryloxy or T;

T = H, alkyl, cycloalkyl, alkoxycarbonyl, carboxy, carboxyalkyl, aryl, heteroaryl, (alkylene)-CONR10R11, CONR10R11 or NR10R11;

R10 = H or alkyl;

R11 = aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aralkyl, heteroaralkyl, heterocyclylalkyl (optionally alkyl substituted by 1 or 2 OH), aryl, heteroaryl, heterocyclyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl or alkoxycarbonylalkyl, or

NR10R11 = heterocyclylamino;

R6 = hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, heterocyclylalkyl, heterocyclylcarbonyl, aminoalkylcarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl or T;

R7, R8 = H, alkyl, cycloalkyl, heterocyclylalkyl, COR12, (alkylene)-COR12, SO2R14, CONR13R14 or (alkylene)-CONR13R14, or

R6 + R7 or R7 + R8 = 5-8 membered ring;

R13 = H or alkyl;

R14 = aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aralkyl, heteroaralkyl, heterocyclylalkyl (optionally alkyl substituted by 1 or 2 OH), aryl, heteroaryl, heterocyclyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl or alkoxycarbonylalkyl, or

NR13R14 = heterocyclylamino;
R12 = alkoxy, OH, alkylamino, dialkylamino or heterocyclyl;
R9 = H, alkyl, PO(OR15)2, COR16 or CHR17NR18R19; and
R15-R19 = H or alkyl; or
NR18R19 = heterocycloamino.
ACTIVITY - Cytostatic; Anti-HIV; Antidiabetic; Antipsoriatic; Antiarthritic; Antirheumatic; Antiinflammatory; Immunosuppressive; Vasotropic; Osteopathic; Antiarteriosclerotic; Uropathic; Antiangiogenetic; Cardiant; Hepatotropic.
Tests are described, but no results are given.
MECHANISM OF ACTION - Protein-Kinase-Modulator; Protein-Kinase-Inhibitor; Receptor-Tyrosine-Kinase-Modulator; Non-receptor-Tyrosine-Kinase-Modulator; Serine-Threonine-Kinase-Modulator.
Tests are described, but no results are given.
USE - Used for treating cancer (e.g. squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer), diabetes, autoimmune disorder, hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Hippel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, inflammatory disorder and cardiovascular disorder (all claimed). (I) Are used for treating cancers such as non small cell lung cancer (NSCLC), bone cancer, pancreatic cancer, skin cancer, cutaneous or intraocular melanoma, uterine cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, gynecologic tumors (e.g. uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the endometrium, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g. cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e.g. renal cell carcinoma, carcinoma of the renal pelvis), pediatric malignancy, neoplasms of the central nervous system (e.g. primary CNS lymphoma, spinal axis tumors, brain stem gliomas or pituitary adenomas), Barrett's esophagus (premalignant syndrome), neoplastic cutaneous disease, mycoses fungoides, benign prostatic hypertrophy, diabetic retinopathy, retinal ischemia, retinal neovascularization, hepatic cirrhosis, angiogenesis, atherosclerosis, immunological disease and renal disease. (I) Are also used for preventing embryo implantation and are useful as birth control agents.
ADVANTAGE - (I) Have less toxicity and improved bioavailability.
Dwg.0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; GI; DCN
MANUAL CODES: CPI: B14-C03; B14-C09; B14-D06; B14-F01G; B14-F02; B14-F07; B14-G03; B14-H01; B14-K01; B14-N03; B14-N10; B14-N12; B14-N17C; B14-P01; B14-S04

L16 ANSWER 18 OF 19 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-019119 [01] WPIDS
DOC. NO. CPI: C2003-004834
TITLE: New 3-(pyrrol-2-ylmethylidene)-2-**indolinone** derivatives useful as **protein kinase inhibitors** for treating e.g. cancer, diabetes, restenosis, fibrosis, psoriasis, von Hippel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis.
DERWENT CLASS: B02
INVENTOR(S): KOENIG, M; NEMATALLA, A S; SUN, C L; **TANG, P C**; VOJKOVSKY, T; **WEI, C C**; ZHOU, Y

PATENT ASSIGNEE(S): (SUGE-N) SUGEN INC
COUNTRY COUNT: 100
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2002081466	A1	20021017	(200301)*	EN	194	C07D403-06
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW						
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW						
US 2003100555	A1	20030529	(200337)			A61K031-5377
AU 2002307183	A1	20021021	(200433)			C07D403-06
US 2004186161	A1	20040923	(200463)			C07D403-02
US 6797725	B2	20040928	(200465)			A61K031-403

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002081466	A1	WO 2002-US11001	20020409
US 2003100555	A1 Provisional	US 2001-282630P	20010409
		US 2002-118321	20020409
AU 2002307183	A1	AU 2002-307183	20020409
US 2004186161	A1 Provisional	US 2001-282630P	20010409
	Div ex	US 2002-118321	20020409
		US 2004-816957	20040405
US 6797725	B2 Provisional	US 2001-282630P	20010409
		US 2002-118321	20020409

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002307183	A1 Based on	WO 2002081466

PRIORITY APPLN. INFO: US 2001-282630P 20010409; US 2002-118321 20020409; US 2004-816957 20040405
INT. PATENT CLASSIF.:
MAIN: A61K031-403; A61K031-5377; C07D403-02; C07D403-06
SECONDARY: A61K031-404; A61K031-405; A61K031-454; A61K031-496; A61P035-00; C07D209-02; C07D233-02; C07D403-14; C07D413-14; C07F009-09

BASIC ABSTRACT:

WO 200281466 A UPAB: 20030101
NOVELTY - 3-(Pyrrol-2-ylmethylidene)-2-indolinone derivatives or their salts are new.

DETAILED DESCRIPTION - 3-(Pyrrol-2-ylmethylidene)-2-indolinone derivatives of formula (I) or their salts are new.

R1 and R2 = H, halo, alkyl, alkylthio, nitro, trihalomethyl, OH, hydroxyalkyl, alkoxy, cyano, (hetero)aryl, -C(O)R7, NR8R9, -NR8C(O)R9, -SO2R8 or -S(O)2NR8R9;

R7 = alkyl, amino, OH, alkoxy, (hetero)aryl, (hetero)aryloxy, heterocycle or aminoalkylamino;

R8 and R9 = H, alkyl or (hetero)aryl;

N(R8+R9) = saturated heterocycloamino;

R3 = (hydroxy)alkyl, -aminoalkyl, -C(O)R7, (hetero)aryl or H;

R4 = H, alkyl, -C(O)R7 or (hetero)aryl;

R5 = H or -COR10;
R10 = alkyl, alkoxy, OH, aryloxy, (hetero)aryl, heterocyle, alkylamino, dialkylamino or -NR11R12;
R12 = aminoalkyl, heteroaralkyl or heterocyclylalkyl (in which the alkyl chain is optionally mono to di substituted by OH), hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl;
R4+R5 = (CH2)4- or -(CH2)mCO(CH2)n-;
n = 0 - 3;
R6 = -OR13 or -NR15R16;
n+m = 3;
R13 = carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl or alkoxyalkyl (in which the alkyl chains are optionally mono- to di-substituted by OH and optionally one or two carbon atoms in the alkyl chain are replaced by oxygen or -NR14-, -S- or -SO2-), alkyl, trifluoromethyl, (hetero)aryl, heterocyclyl or monosaccharides;
R15 and R16 = carboxyalkyl, aminoalkyl, phosphonooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl or alkoxyalkyl (in which the alkyl chains are optionally mono to di substituted with OH and optionally one or two carbon atoms in the alkyl chain are replaced by oxygen, -NR14, -S or -SO2), H, alkyl, sulfooxyalkyl or (hetero)aryl;
N(R15+R16) = optionally saturated heterocycloamino; and
R11 and R14 = H or alkyl.
ACTIVITY - Immunosuppressive; Cytostatic; Antidiabetic; Antiinflammatory; Anti-HIV; Osteopathic; Antiarthritic; Vasotropic; Antipsoriatic; Antirheumatic; Cardiovascular gen.; Anti-tumor; Ophthalmological; Antiarteriosclerotic.
MECHANISM OF ACTION - Protein kinase (preferably receptor tyrosine, non-receptor tyrosine and serine-threonine) inhibitor.
Test details are given, but no results are given.
USE - For treating or preventing a protein kinase related disorder e.g. (receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder, a serine-threonine kinase related disorder, EGFR related disorder, a PDGFR related disorder, IGFR related disorder or flk related disorder), cancer e.g. (carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer or gastrointestinal cancer), diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Hippel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and cardiovascular disorder (claimed) as prodrugs. Also for treating tumor and leukemia, arteriosclerosis, arthritis and diabetic retinopathy.
ADVANTAGE - The compound exhibits protein kinase modulating ability. The compound is bioavailable and have low toxicity.
Dwg.0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; GI; DCN
MANUAL CODES: CPI: B05-B01M; B06-D01; B14-C03; B14-C09A; B14-C09B; B14-D06; B14-F01; B14-F01G; B14-F02F2; B14-F07; B14-G02D; B14-H01A; B14-H01B; B14-N17C; B14-S04

L16 ANSWER 19 OF 19 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2002-488505 [52] WPIDS
CROSS REFERENCE: 2000-195588 [17]; 2001-059945 [07]; 2004-040992 [04]
DOC. NO. CPI: C2002-138680
TITLE: New **indolinone** derivatives are **protein kinase inhibitors** and modulators, useful in the treatment of cell proliferative diseases e.g. cancer, atherosclerosis, arthritis, restenosis, and metabolic diseases such as diabetes.

DERWENT CLASS: B02
INVENTOR(S): HIRTH, K P; MCMAHON, G; SHAWVER, L K; SUN, L; **TANG, P C**
PATENT ASSIGNEE(S): (HIRT-I) HIRTH K P; (MCMA-I) MCMAHON G; (SHAW-I) SHAWVER L K; (SUNL-I) SUN L; (TANG-I) TANG P C
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 2002022626	A1	20020221	(200252)*		85	A61K031-40

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002022626	A1 Div ex	US 1997-915366	19970820
		US 2000-617529	20000713

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2002022626	A1 Div ex	US 6147106

PRIORITY APPLN. INFO: US 1997-915366 19970820; US 2000-617529 20000713
INT. PATENT CLASSIF.:
MAIN: A61K031-40
SECONDARY: A61K031-535; C07D209-02; C07D413-00
BASIC ABSTRACT:

US2002022626 A UPAB: 20040421

NOVELTY - A combinatorial library of indolinone compounds comprising at least 10 indolinones that can be formed by reacting oxindoles with aldehydes.

DETAILED DESCRIPTION - A combinatorial library of indolinone compounds comprising at least 10 indolinones that can be formed by reacting oxindoles with aldehydes.

INDEPENDENT CLAIMS are included for:

(1) a method of preparation of an indoline comprising:

(a) creating a combinatorial library of indolinones by reacting a series of indolinones with a series of aldehydes;

(b) testing the indolinones in biological assays;

(c) selecting one or more indolinones with favorable activity; and

(d) synthesizing one of more of the indolinones selected from step (c);

(2) a method of preparing an indolinone compound (I) comprising reacting an aldehyde and oxindole and separating the indolinone compound from the reactants;

(3) a 3-((indol-3-yl)methylene)-2-indolinone compound (I) having a substituent at the 1' position, (X), of the indole selected from the substituents listed in the definitions field.

(4) an indolinone compound (II) having a substituent at the 5 position of the oxindole ring, (X1), selected from the substituents listed in the definitions field; and

(5) a compound of formula (XXI).

A = a 5-6 membered ring comprising atoms selected from O, C, S and/or N;

m = 0-2;

R1 = H, 1-6C alkyl or 2-6C alkanoyl;

one of R2 and R3 = H and the other is Q1;

Q1 = 1-6C alkyl (substituted by 1-3 OH), SO3R4'', SO2NHR5'', COOR6'',

COHNR7'', NHSO2R8'', N(R9'')2, NHR9'', OR9'', NHCOR10'', OOCR10'', CH2OOCR10'', NHCONH2, NH-C(NH2)=NH, C(NH2)=NH, CH2NHC(NH2)=NH, CH2NH2, OPO(OH)2, CH2OPO(OH)2, PO(OH)2 or a group of formula (i);

R4'' = H or 1-6C alkyl optionally substituted by 1-3 OH;

R5'' = R4'' or -(CH2)n-N(1-6C alkyl)2

n = 2-3;

R6'' = phenyl or 1-6C alkyl optionally substituted by phenyl or 1-3 OH;

R7'' = H, phenyl or 1-6C alkyl optionally substituted by phenyl or 1-3 OH;

R8'' = 1-6C alkyl or phenyl optionally substituted by halo or 1-4C alkyl;

R9'' = 2-6C alkyl substituted by 1-3 OH;

R10'' = 1-6C alkyl substituted by 1-3 OH;

X'' = CH2, SO2, CO, NHCO(CH2)p;

p = 1-3;

Z' = CH2, O, N-R11''; and

R11'' = H or R9''.

ACTIVITY - Cytostatic; Antidiabetic; Antiarteriosclerotic; Antiarthritic; Cardiant; Vasotropic; Antilipemic; Neuroprotective; Nootropic; Vulnerary; Dermatological; Antiinflammatory.

MECHANISM OF ACTION - Protein kinase modulators/inhibitors, especially raf, FLK, FGFR (fibroblast growth factor receptor) and PGFR (platelet derived growth factor) protein kinase modulators or inhibitors.

In FLK-1 kinase biological inhibition assays 3-(1-methyl-1H-indol-3-ylmethylene)-1,3-dihydro-indol-2-one and 5-amino-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydro-indol-2-one exhibited IC50 values of 0.7 microM and 1.2 microM respectively.

USE - (I), (IA), (II), (IIA) (XIX)and (XX) are useful for treating a disease related to unregulated tyrosine kinase signal transduction associated with an aberration in a signal transduction pathway characterized by an interaction between a protein kinase and a natural binding partner. The compounds are useful for treating e.g. cell proliferative diseases such as cancer, atherosclerosis, arthritis, restenosis and metabolic diseases such as diabetes as well as abnormal angiogenesis and vasculogenesis, wound healing, psoriasis and inflammation. The compounds can also be used to treat neurodegenerative diseases, e.g. Parkinson's Disease and Alzheimer's Disease.

Dwg.0/0

FILE SEGMENT: CPI
FIELD AVAILABILITY: AB; GI; DCN
MANUAL CODES: CPI: B05-B01M; B06-D01; B06-H; B07-H; B14-C03; B14-C09; B14-D06; B14-F01G; B14-F02; B14-F07; B14-H01; B14-J01; B14-J01A3; B14-J01A4; B14-N17B; B14-N17C; B14-S04

```
=> => fil reg; d stat que l19; fil capl uspatf toxcenter; s l19
FILE 'REGISTRY' ENTERED AT 16:25:15 ON 10 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 FEB 2005  HIGHEST RN 828241-21-0
DICTIONARY FILE UPDATES:   9 FEB 2005  HIGHEST RN 828241-21-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

L17                 STR
```



this query includes cmpd of s/n 17

```
VAR G1=35/51/46
VAR G2=12/13/14/18/19/24/25/28/30/31
VAR G3=O/S/N
VAR G4=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT  51
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M4-X5 C  X2 N  AT  51

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  49

STEREO ATTRIBUTES: NONE
```

L19 39 SEA FILE=REGISTRY SSS FUL L17

100.0% PROCESSED 1290 ITERATIONS 39 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 16:25:15 ON 10 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:25:15 ON 10 FEB 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:25:15 ON 10 FEB 2005
COPYRIGHT (C) 2005 ACS

L22 9 L19

=> dup rem l22
PROCESSING COMPLETED FOR L22
L23 7 DUP REM L22 (2 DUPLICATES REMOVED)
ANSWERS '1-3' FROM FILE CAPLUS
ANSWERS '4-7' FROM FILE USPATFULL

=> d ibib ed abs hitstr 1-7; fil hom

L23 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2003:301079 CAPLUS
DOCUMENT NUMBER: 138:304310
TITLE: Preparation of 3-[4-(heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
INVENTOR(S): Mattson, Matthew; Vojkovsky, Tomas; Liang, Congxin; Tang, Peng Cho; Guan, Huiping
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031438	A1	20030417	WO 2002-US32354	20021010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003130235	A1	20030710	US 2002-268082	20021010
US 6642232	B2	20031104		
EP 1434774	A1	20040707	EP 2002-776202	20021010

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
BR 2002013185 A 20040914 BR 2002-13185 20021010
PRIORITY APPLN. INFO.: US 2001-328226P P 20011010
WO 2002-US32354 W 20021010
OTHER SOURCE(S): MARPAT 138:304310
ED Entered STN: 18 Apr 2003
GI



I



II

AB Title compds. I [R = H, PO2R5, acyl, alkyl, etc.; R1 = H, alkyl, alkoxy, OH, CF3, etc.; R2 = H, alkyl, heteroaryl, alkoxy, etc.; R3-5 = H, alkyl; A = (un)substituted heterocycloamino; Het = cycloalkylaminoalkyl, heteroaryl, etc.; X = amino, alkoxy; n = 0-1] are prepared For instance, 4-amino-1-benzylpiperidine is converted to 4-(morpholin-4-yl)piperidine (i. DMF, K2CO3, 50°; ii. MeOHaq, H2-Pd/C) and coupled to prior art (Z)-3-(3,5-dimethyl-4-carboxy-1H-pyrrol-2-ylmethylidene)-5-fluoro-1,3-dihydro-2H-indol-2-one (DMF, BOP, Et3N) to give II. I inhibit kinases, in particular VEGFR, PDGFR and c-KIT kinases (no data) and are useful for the treatment of glioblastoma, melanoma, etc.

IT **511295-70-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-[4-(heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivs. as VEGFR and PDGFR kinase inhibitors)

RN 511295-70-8 CAPLUS

CN Piperidine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2002:31440 CAPLUS
DOCUMENT NUMBER: 136:102386
TITLE: Preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Wei, Chung Chen; Huang, Ping; Cui, Jingron
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002551	A1	20020110	WO 2001-US20768	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414468	AA	20020110	CA 2001-2414468	20010629
US 2002187978	A1	20021212	US 2001-894902	20010629
US 6635640	B2	20031021		
EP 1296975	A1	20030402	EP 2001-948830	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004502686 T2 20040129 JP 2002-507803 20010629
US 2004097497 A1 20040520 US 2003-648810 20030827
PRIORITY APPLN. INFO.: US 2000-215654P P 20000630
US 2001-894902 A3 20010629
WO 2001-US20768 W 20010629
OTHER SOURCE(S): MARPAT 136:102386
ED Entered STN: 11 Jan 2002
GI



I



II

AB Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, etc.; Het = (un)substituted aromatic heterocycle containing at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted aromatic heterocycle containing not more than two N atoms, 5-membered ring (un)substituted heterocycle containing N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.] with some exceptions, were prepared Included are 75 synthetic examples and results for several protein tyrosine kinase assays for those compds. For instance, 4-bromoindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf)•CH2Cl2, 80°C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine•HCl (THF, Pd(PPh3)4, NaOH, 70°C, 6 h) to give the indole which was treated with C5H5N•Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dyhydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 mM for FGFR-1 tyrosine kinase and 0.03 mM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.

IT **388116-44-7P 388116-45-8P 388116-47-0P**
388116-50-5P 388116-51-6P 388116-52-7P
388116-54-9P 388116-55-0P 388116-56-1P
388116-57-2P, 3-(1H-Indol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-58-3P**, 4-(Pyridin-4-yl)-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one
388116-60-7P 388116-61-8P 388116-64-1P
388116-65-2P 388116-66-3P 388116-68-5P
388116-70-9P, 3-(5-Methylthiophen-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-71-0P**, 3-(4-Morpholin-4-ylbenzylidene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
388116-72-1P 388116-73-2P 388116-74-3P
388116-76-5P 388117-14-4P 388117-16-6P, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-2-yl-1,3-dihydroindol-2-one **388117-17-7P**, 3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyrimidin-5-yl-1,3-dihydroindol-2-one **388117-19-9P**
388117-21-3P 388117-22-4P, 4-(6-Aminopyridin-3-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-

1,3-dihydroindol-2-one **388117-23-5P 388117-24-6P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-
4-pyridin-3-yl-1,3-dihydroindol-2-one **388117-25-7P**
388117-26-8P, 5-[3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-
ylcarbonyl)pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-
yl]nicotinic acid **388117-28-0P 388117-29-1P**,
4-(2-Aminopyrimidin-5-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-
ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one
388117-30-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug; preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones
and their use as protein kinase inhibitors)

RN 388116-44-7 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-
ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA
INDEX NAME)



RN 388116-45-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-4-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-47-0 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-
ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-50-5 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-51-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-52-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)



RN 388116-54-9 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-55-0 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-56-1 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-57-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 388116-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-pyridinyl)-3-[(4,5,6,7-tetrahydro-1H-
indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 388116-60-7 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-
indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-61-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-
indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-64-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-65-2 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-66-3 CAPLUS
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-68-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388116-70-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-71-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[4-(4-morpholinyl)phenyl]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



dlm 17

RN 388116-72-1 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[4-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 388116-73-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-74-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 388116-76-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-14-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-16-6 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-17-7 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA

INDEX NAME)



RN 388117-19-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-21-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-22-4 CAPLUS
CN Piperazine, 1-[[5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-23-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-24-6 CAPLUS
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-25-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-26-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2354591	AA	20000622	CA 1999-2354591		19991209
BR 9916223	A	20010904	BR 1999-16223		19991209
EP 1149093	A1	20011031	EP 1999-966933		19991209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200101858	T2	20011221	TR 2001-200101858		19991209
AU 760039	B2	20030508	AU 2000-22815		19991209
CN 1136216	B	20040128	CN 1999-814585		19991209
US 6307056	B1	20011023	US 1999-464466		19991215
ZA 2001004320	A	20020826	ZA 2001-4320		20010525
PRIORITY APPLN. INFO.:			US 1998-112590P	P	19981217
			US 1999-149028P	P	19990816
			WO 1999-EP9673	W	19991209

OTHER SOURCE(S): MARPAT 133:43433
ED Entered STN: 23 Jun 2000
GI



I

AB Title compds. [I; A = (substituted) aryl, heteroaryl; R2 = H, halo, OR4, NR6R7, COR4, CO2R4, cyano, NO2, SO2R4, SO2NR6R7, etc.; R3 = H, OR4, COR4, CO2R4, CONR6R7, halo, cyano, NR6R7, perfluoroalkyl, (substituted) alkyl, etc.; R4 = H, (substituted) alkyl, cycloalkyl, heterocyclyl; R6, R7 = H, (substituted) alkyl, cycloalkyl, COR8, CO2R8, SO2R8, etc.; NR6R7 = (substituted) 3-7 membered ring; R8 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; X = N, CH], were prepared Thus, (Z)-1,3-dihydro-4-iodo-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one (preparation given) was heated with phenylboronic acid, Pd(OAc)2, Et3N, and tri-O-tolylphosphine in DMF at 100° for 24 h to give 85% (Z)-1,3-dihydro-4-phenyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one. Tested I inhibited SAPK with IC50<0.15 μM.

IT **276251-34-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)

RN 276251-34-4 CAPLUS
CN 2H-Indol-2-one, 4-(2,6-dimethoxy-4-pyrimidinyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2004:127513 USPATFULL
TITLE: 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho, Moraga, CA, UNITED STATES
Wei, Chung Chen, Foster City, CA, UNITED STATES
Huang, Ping, Mountain View, CA, UNITED STATES
Cui, Jingrong, Foster City, CA, UNITED STATES
PATENT ASSIGNEE(S): Sugen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097497	A1	20040520
APPLICATION INFO.:	US 2003-648810	A1	20030827 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-894902, filed on 29 Jun 2001, GRANTED, Pat. No. US 6635640

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215654P	20000630 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 4661
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases ("PKs"), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **388116-44-7P 388116-45-8P 388116-47-0P 388116-50-5P 388116-51-6P 388116-52-7P 388116-54-9P 388116-55-0P 388116-56-1P 388116-57-2P**, 3-(1H-Indol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-58-3P**, 4-(Pyridin-4-yl)-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one

388116-60-7P 388116-61-8P 388116-64-1P
388116-65-2P 388116-66-3P 388116-68-5P
388116-70-9P, 3-(5-Methylthiophen-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-71-0P**, 3-(4-Morpholin-4-ylbenzylidene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
388116-72-1P 388116-73-2P 388116-74-3P
388116-76-5P 388117-14-4P 388117-16-6P,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-2-yl-1,3-dihydroindol-2-one **388117-17-7P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyrimidin-5-yl-1,3-dihydroindol-2-one **388117-19-9P**
388117-21-3P 388117-22-4P, 4-(6-Aminopyridin-3-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one **388117-23-5P 388117-24-6P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-3-yl-1,3-dihydroindol-2-one **388117-25-7P**
388117-26-8P, 5-[3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-28-0P 388117-29-1P**,
4-(2-Aminopyrimidin-5-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one
388117-30-4P
(drug; preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-44-7 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-45-8 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



dkm 17

RN 388116-47-0 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-50-5 USPATFULL
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-51-6 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-52-7 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)



RN 388116-54-9 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-55-0 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-56-1 USPATFULL
CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-57-2 USPATFULL

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 388116-58-3 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-pyridinyl)-3-[(4,5,6,7-tetrahydro-1H-
indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 388116-60-7 USPATFULL
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-
indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-61-8 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-
indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-64-1 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-65-2 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-66-3 USPATFULL
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-68-5 USPATFULL
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388116-70-9 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-71-0 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[[4-(4-morpholinyl)phenyl]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-72-1 USPATFULL
CN 1-Piperazinecarboxaldehyde, 4-[4-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]phenyl]- (9CI) (CA INDEX NAME)



ilm 17

RN 388116-73-2 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-74-3 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 388116-76-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-14-4 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-16-6 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-17-7 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI)

(CA INDEX NAME)



RN 388117-19-9 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-21-3 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-22-4 USPATFULL
CN Piperazine, 1-[[5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-23-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-24-6 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-25-7 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-26-8 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-28-0 USPATFULL
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-29-1 USPATFULL
CN Piperazine, 1-[[5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-

4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **388116-49-2P**, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
(preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)
RN 388116-49-2 USPATFULL
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2003:188442 USPATFULL
TITLE:	3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
INVENTOR(S):	Mattson, Matthew, Santa Clara, CA, UNITED STATES Vojkovsky, Tomas, San Mateo, CA, UNITED STATES Liang, Congxin, Sunnyvale, CA, UNITED STATES Tang, Peng Cho, Morago, CA, UNITED STATES Guan, Huiping, Foster City, CA, UNITED STATES
PATENT ASSIGNEE(S):	Sugen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003130235	A1	20030710	
	US 6642232	B2	20031104	
APPLICATION INFO.:	US 2002-268082	A1	20021010	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-328226P	20011010 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1

LINE COUNT: 2285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to certain 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives that inhibit kinases, in particular VEGFR and/or PDGFR kinases. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **511295-70-8P**
(preparation of 3-[4-(heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivs. as VEGFR and PDGFR kinase inhibitors)
RN 511295-70-8 USPATFULL
CN Piperidine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 6 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2002:330293 USPATFULL
TITLE: 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho, Moraga, CA, UNITED STATES
Wei, Chung Chen, Foster City, CA, UNITED STATES
Huang, Ping, Mountain View, CA, UNITED STATES
Cui, Jingrong, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002187978	A1	20021212	
	US 6635640	B2	20031021	
APPLICATION INFO.:	US 2001-894902	A1	20010629	(9)

NUMBER DATE

Searched by Barb O'Bryen, STIC 2-2518

PRIORITY INFORMATION:	US 2000-215654P 20000630 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109
NUMBER OF CLAIMS:	29
EXEMPLARY CLAIM:	1
LINE COUNT:	4655

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases ("PKs"), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **388116-44-7P 388116-45-8P 388116-47-0P**
388116-50-5P 388116-51-6P 388116-52-7P
388116-54-9P 388116-55-0P 388116-56-1P
388116-57-2P, 3-(1H-Indol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-58-3P**, 4-(Pyridin-4-yl)-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one
388116-60-7P 388116-61-8P 388116-64-1P
388116-65-2P 388116-66-3P 388116-68-5P
388116-70-9P, 3-(5-Methylthiophen-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one **388116-71-0P**, 3-(4-Morpholin-4-ylbenzylidene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
388116-72-1P 388116-73-2P 388116-74-3P
388116-76-5P 388117-14-4P 388117-16-6P,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-2-yl-1,3-dihydroindol-2-one **388117-17-7P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyrimidin-5-yl-1,3-dihydroindol-2-one **388117-19-9P**
388117-21-3P 388117-22-4P, 4-(6-Aminopyridin-3-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one **388117-23-5P 388117-24-6P**,
3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-4-pyridin-3-yl-1,3-dihydroindol-2-one **388117-25-7P**
388117-26-8P, 5-[3-[(3,5-Dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indol-4-yl]nicotinic acid **388117-28-0P 388117-29-1P**,
4-(2-Aminopyrimidin-5-yl)-3-[(3,5-dimethyl-4-(4-methylpiperazin-1-ylcarbonyl)pyrrol-2-yl)methylene]-1,3-dihydroindol-2-one
388117-30-4P
(drug; preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-44-7 USPATFULL

CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-45-8 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-47-0 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 388116-50-5 USPATFULL
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 388116-51-6 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-52-7 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)



RN 388116-54-9 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(ethoxycarbonyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-55-0 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-56-1 USPATFULL
CN 1H-Pyrrole-3-acetic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-57-2 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-58-3 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-4-(4-pyridinyl)-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 388116-60-7 USPATFULL
CN 1H-Pyrrole-2-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-61-8 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 388116-64-1 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-65-2 USPATFULL

CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-66-3 USPATFULL
CN 2H-Isoindole-1-carboxylic acid, 3-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 388116-68-5 USPATFULL
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 388116-70-9 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 388116-71-0 USPATFULL
CN 2H-Indol-2-one, 1,3-dihydro-3-[[4-(4-morpholinyl)phenyl]methylene]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



clm 17

RN 388116-72-1 USPATFULL
CN 1-Piperazinecarboxaldehyde, 4-[4-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]phenyl]- (9CI) (CA INDEX NAME)



clm 17

RN 388116-73-2 USPATFULL
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 388116-74-3 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 388116-76-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-14-4 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-16-6 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(2-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-17-7 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-19-9 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(5-pyrimidinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-21-3 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-22-4 USPATFULL
CN Piperazine, 1-[[5-[[4-(6-amino-3-pyridinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-23-5 USPATFULL
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-24-6 USPATFULL
CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-25-7 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[[4-(ethoxycarbonyl)-5-methyl-3-[3-(4-methyl-1-piperazinyl)propyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-26-8 USPATFULL
CN 3-Pyridinecarboxylic acid, 5-[3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-4-yl]- (9CI) (CA INDEX NAME)



RN 388117-28-0 USPATFULL
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-29-1 USPATFULL
CN Piperazine, 1-[[5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 USPATFULL
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **388116-49-2P**, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
(preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)
RN 388116-49-2 USPATFULL
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L23 ANSWER 7 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2001:185487 USPATFULL
TITLE: 4-aryloxindoles
INVENTOR(S): Corbett, Wendy Lea, Randolph, NJ, United States
Luk, Kin-Chun, North Caldwell, NJ, United States
Mahaney, Paige E., Montclair, NJ, United States

PATENT ASSIGNEE(S): Hoffman-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6307056	B1	20011023
APPLICATION INFO.:	US 1999-464466		19991215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112590P	19981217 (60)
	US 1999-149028P	19990816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Johnston, George W., Rocha-Tramaloni, Patricia S.
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 3094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are 4-aryloxindoles that inhibit or modulate protein kinases, in particular JNK protein kinases. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are useful as anti-inflammatory agents, particularly useful in the treatment of rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing the foregoing compounds, as well as methods for the treatment and/or control of inflammation, particularly in the treatment or control of rheumatoid arthritis, using said compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **276251-34-4P**
(preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases)
RN 276251-34-4 USPATFULL
CN 2H-Indol-2-one, 4-(2,6-dimethoxy-4-pyrimidinyl)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



FILE 'HOME' ENTERED AT 16:26:13 ON 10 FEB 2005

=> d saved

NAME	CREATED	NOTES/TITLE

COO010FAM/A	TEMP	1 ANSWER IN FILE REGISTRY
COO102FULL/A	TEMP	6122 ANSWERS IN FILE REGISTRY
COO102SUB/A	TEMP	3987 ANSWERS IN FILE REGISTRY
COO530FULL/A	TEMP	109 ANSWERS IN FILE REGISTRY
COO530STR1/Q	TEMP	STRUCTURE
COO530SUB/A	TEMP	6 ANSWERS IN FILE REGISTRY
COO783FAM/A	TEMP	10 ANSWERS IN FILE REGISTRY
PAS485FULL/A	TEMP	211 ANSWERS IN FILE REGISTRY
WAR397FULL/A	TEMP	57 ANSWERS IN FILE REGISTRY
WAR397SUB/A	TEMP	10 ANSWERS IN FILE REGISTRY
WAR636FULL/A	TEMP	191 ANSWERS IN FILE REGISTRY
WAR810FULL/A	TEMP	39 ANSWERS IN FILE REGISTRY
WAR817FULL/A	TEMP	624 ANSWERS IN FILE REGISTRY
WAR946FULL/A	TEMP	21 ANSWERS IN FILE REGISTRY

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	321.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.41

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:26:45 ON 10 FEB 2005



RN 388117-28-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388117-29-1 CAPLUS
CN Piperazine, 1-[[5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 388117-30-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-

4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **388116-49-2P**, 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(pyridin-4-yl)-1,3-dihydroindol-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)
RN 388116-49-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:421132 CAPLUS
DOCUMENT NUMBER: 133:43433
TITLE: Preparation of 4-aryl-3-(azolylmethylidene)-2-oxindoles as inhibitors of JNK protein kinases.
INVENTOR(S): Corbett, Wendy Lea; Luk, Kin-chun; Mahaney, Paige E.
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035909	A1	20000622	WO 1999-EP9673	19991209

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,